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Summary 
Bioactive lipids are central in regulating the inflammatory process and imbalance in 
lipid mediator signaling contributes to progression of pathological conditions such as 
atherosclerosis, allergy, autoimmunity, degenerative diseases and cancer. Phospholipase 
A2 (PLA2) enzymes release fatty acids such as arachidonic acid (AA) and a 
lysophospholipid from cellular membranes. Lysophospholipids can me metabolized to 
biologically active lipid mediators including platelet-activating factor (PAF). PAF is a 
potent mediator of inflammation, but can also exert a range of other physiological and 
pathophysiological processes including apoptosis, proliferation and cancer 
development. AA is a precursor of many bioactive lipid including prostaglandins such 
as prostaglandin E2 (PGE2), a potent immunoregulator and inducer of inflammation, 
fever and pain.  
In particular cytosolic phosholipase A2 (cPLA2Į) is associated with 
inflammation and inflammatory disease as a main enzyme mediating AA release and 
proinflammatory eicosanoid production, and is proposed as a future therapeutic target. 
However, lipid signaling is complex and sophisticatedly regulated, and the downstream 
consequences of cPLA2Į inhibition are not fully understood. The overall objective of 
this thesis was to investigate the role of PLA2 enzymes, in particular cPLA2Į, and 
downstream lipid messengers in cellular signaling mechanisms involved in chronic 
inflammatory disease. In Paper I, we investigated the role of PAF in differentiated 
keratinocytes, a cellular model system for psoriatic skin. We found that PAF did not 
primarily induce pro-inflammatory signaling, but rather proliferative responses possibly 
linking the inflammatory response to re-epithelialization and wound-healing. In the 
second part of this thesis comprising Papers II-IV, we focused on the role of cPLA2Į in 
regulating pro-inflammatory signaling pathways central in the pathogenesis of 
rheumatoid arthritis (RA). In Paper II, we found cPLA2Į to regulate joint-destructive 
and pro-inflammatory effectors induced by tumor necrosis factor (TNF), a “master” 
cytokine in RA. In Papers III and IV, we investigated the role of cPLA2Į in modulating 
TLR-induced signaling. TLRs constitute a central part in the innate immune system 
sensing invading pathogens and tissue injury. However, TLRs can also induce “sterile” 
inflammation by recognizing molecules derived from the host itself, and increased TLR 
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activation is believed to contribute to the pathogenesis of a range of inflammatory and 
autoimmune diseases including RA. We found that cPLA2Į regulates TLR-induced 
activation of the transcription factor NF-țB and expression of several pro-inflammatory 
mediators. We furthermore identified PGE2 and possibly other related prostanoids as 
actors in this mechanism.  
Taken together, our findings expand the understanding of cPLA2Į as a central 
regulator of molecular mechanisms in chronic inflammation, and enlighten the potential 
role of cPLA2Į and PAF in linking the inflammatory and proliferatory processes. 
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1. Introduction 
The field of translational medicine can be described as an effort to carry scientific 
discoveries and knowledge from “bench to bedside”. Basic research advances, such as 
studies of biological processes in cell cultures or animal models, provides an 
understanding of fundamental mechanisms in disease and can be built on to develop 
novel therapies or pinpoint new therapeutic targets. In this thesis, molecular 
mechanisms in inflammation are investigated in cellular model systems, in order to 
expand our understanding of dysregulated signaling processes in chronic inflammatory 
disease. From a translational research point of view, these results can contribute in the 
development of a new therapeutic approach in treating chronic inflammatory diseases. 
 
1.1. Inflammation 
The inflammatory response is part of our natural host-defense system and descriptions 
of its characteristics date back to ancient Egyptian and Greek cultures. More than 2000 
years ago the roman doctor Aulus Celsius described the four hallmarks of inflammation; 
rubor (redness), tumor (swelling), calor (heat) and dolor (pain). Two hundred years 
later, Galen recognized inflammation as a reaction of the body against injury and added 
a fifth characteristic, functio laesa, loss of function, as pictured in Figure 1 [1]. During 
the 20th century a rapid advancement in the understanding of molecular function and 
mechanisms underlying inflammation took place, and our understanding of the 
inflammatory process is still expanding. Acute inflammation is a beneficial host defense 
mechanism protecting the body from infection and other insults, and our health entirely 
relies on its well-functioning. The Scottish surgeon John Hunter wrote in 1794 that 
“Inflammation in itself is not to be considered as a disease but as a salutary operation, 
consequent either to some violence or some disease” [2]. This insight emphasize that 
the inflammatory response is essential to remain healthy and maintain homeostasis.  
When it occurs, it is normally well regulated, self-limiting and resolves rapidly thus 
avoiding excessive damage to the host. However, the outcome of the inflammatory 
process is not always successful resolution and repair of damaged tissue. Chronic 
inflammatory diseases develop as a result of genetic and environmental interplay which 
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is still only partially understood and represent a major challenge. There has been a 
drastic increase in the prevalence of chronic inflammatory diseases since the end of 
World War II, particularly in the western world, possibly due to genetic and epigenetic 
factors in combinations with changes in diet and lifestyle [3, 4]. To understand how the 
highly complex and sophisticated signaling circuits are regulated in inflammation and 
chronic inflammatory disease is of crucial importance when it comes to discovering and 
developing new therapeutic strategies. 
 
Figure 1: Inflammation depicted by five Greeks representing the cardinal signs of inflammation. 
Heat, Redness, Swelling, Pain and Loss of function – first described by Celcius more than two hundred 
years ago, and as relevant today as they were then. From Lawrence et al. 2002, with permission [5].  
 
1.1.1. The course of inflammation 
Inflammation involves interactions between many different cell types, and production of 
and response to numerous chemical signaling mediators. Our immune system is divided 
into two general types; the adaptive immune system and the innate immune system. The 
innate immune system constitutes a first-line defense in turn activating the adaptive 
immune system; a more specific, but slower defense mechanism evolving throughout 
our life. By rearrangement of the immunoglobulin genes and development of pathogen-
specific antigens, immune cells develop immunological memory. Specific pathogens 
and infected cells can thereby be recognized and destructed. The innate (non-specific) 
immune system has no antigenic memory and is not affected by previous exposure to 
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infectious agents. The innate immune response is triggered by entrance of “foreign 
material” such as pathogens and allergens, tissue damage or non-pathogenic materials 
and is initiated by increased blood-flow to the affected area. A cascade of events is then 
effectuated including production of a variety of inflammatory mediators including 
cytokines, vasoactive mediators and lipid mediators such as eicosanoids. The main and 
most immediate effect of these mediators is that leukocytes, normally restricted to the 
blood-flow, is recruited and gain access to the extravascular tissue at the site of action 
through increased capillary permeability [6]. Further production of inflammatory 
mediators cause continuant recruitment of immune cells and perpetuate the 
inflammatory response until resolution signals are effectuated [7]. This acute 
inflammatory response can be triggered within minutes, and may persist for several 
days. Negative feed-back mechanisms such as inhibition of pro-inflammatory signaling 
cascades, production of anti-inflammatory or pro-resolving cytokines and lipid 
mediators, shedding of receptors for inflammatory molecules and activation of 
regulatory cells are central in resolution of inflammation [8, 9].  
 
1.1.2. Inflammation and wound healing  
In response to tissue injury, various intercellular and intracellular processes are 
activated and coordinated in order to restore tissue integrity and homeostasis [10]. The 
first stage of wound healing is the acute inflammatory response acting to prevent blood 
and fluid loss through the coagulation cascade, to remove dead or dying tissues and to 
prevent infection. The second stage occurring 2-10 days after wounding is characterized 
by new tissue formation, and involves cellular proliferation and migration of various 
cell types including keratinocytes and fibroblasts, and angiogenesis. During the third 
stage – tissue remodeling – feed-back loops terminate all activated processes and 
homeostasis is restored; a process which can last for a year or more [10]. Lipid 
mediators including eicosanoids, endocannabinoids and sphingolipids play critical roles 
in regulating wound healing and tissue repair through modulation of the inflammatory 
process [11]. Interestingly, microarray studies have revealed that in healing skin 
wounds, the gene expression patterns strongly resembles that of highly malignant 
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tumors [12], emphasizing the link between the inflammatory process, proliferation and 
cancer development. 
 
1.1.2. Cytokines and cytokine receptors 
Cytokines are a large family of relatively small, secreted non-enzymatic peptide 
hormones including chemokines, interferons, interleukins and tumor necrosis factors 
[13]. Through specific receptors, cytokines elicit a range of physiological effects 
including regulation of inflammation and immune responses. The cytokine network is 
normally self-regulating, balancing the expression of soluble receptors, receptor 
antagonists and antibodies to cytokines. Dysregulation of the equilibrium between pro- 
and anti-inflammatory cytokines is a driving force in pathologic inflammation (Figure 
2). Interleukin (IL)-1ȕ, IL-6, and TNF are central and pleiotropic effectors in the 
inflammatory response, and will be briefly described below focusing on their role in 
human disease.   
 
Figure 2: Cytokine balance in inflammatory disease. In chronic inflammatory disease, the normally 
tightly regulated balance between pro- and anti-inflammatory cytokines is skewed. IL-6 and TGFȕ are 
placed at both sides of the fulcrum, as they can elicit both pro- and anti-inflammatory effects depending 
on stimuli, cell type and tissue. IFN-interferon; GM-CSF-granulocyte–macrophage colony-stimulating 
factor; MCP-1-monocyte chemotactic protein-1; TGBȕ- transforming growth factor ȕ; IL-1RA-
interleukin-1 receptor antagonist. Modified from Arend 2001, with permission [14]. 
 
IL-1ȕ is a member of the IL-1 superfamily and is central in innate immune 
responses and the pathogenesis of a range of inflammatory disorders. An inactive IL-1ȕ 
precursor (proIL-1ȕ) is produced by transcriptional regulation upon pro-inflammatory 
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stimuli including  TNF or IL-1ȕ itself [15]. Active IL-1ȕ is produced by cleavage of 
proIL-1ȕ by caspase-1 activity. Caspase-1 is activated by a protein complex called the 
inflammasome, which plays a crucial role in IL-1ȕ production and is implicated in 
several inflammatory and autoimmune disorders [16]. There are two IL-1ȕ receptors; 
IL-1R1 is the main receptor mediating cellular signaling cascades, whereas IL-1R2 may 
act as a decoy receptor suppressing IL-1ȕ signaling [17]. The IL-1R family contains a 
cytoplasmic Toll/IL-1 receptor (TIR) domain [18], thus sharing commonalities with the 
toll-like receptor (TLR) signaling pathways (TLR signaling will be described below). 
IL-1 receptor antagonist (IL-1Ra) is a naturally produced inhibitor of IL-1ȕ signaling, 
and imbalance between IL-1Ra and IL-1ȕ is implicated in a number of diseases [19]. 
The central role of IL-1ȕ in human disease is emphasized by the multiple clinical trials 
where IL-1ȕ-blocking biologics (including receptor antagonists, soluble decoy 
receptors, and monoclonal anti-interleukin-1ȕ antibodies) are shown effective in 
ameliorating a variety of inflammatory diseases such as rheumatoid arthritis (RA), type 
II diabetes and Behcet's disease [20]. 
IL-6 is a pleiotropic actor in the immune response, and is associated with several 
autoimmune, chronic inflammatory and proliferative diseases including multiple 
sclerosis, RA and cancer [21]. The IL-6 receptor (IL-6R) is expressed in two forms, 
soluble (sIL-6R) and membrane-bound. Upon ligand binding, the IL-6R signals through 
the JAK1–STAT3, RAS–MAPK, and PI3K–AKT pathways to induce transcription of 
genes involved in physiological, pro-inflammatory and anti-inflammatory processes 
including survival, proliferation, differentiation, osteogenesis/osteolysis, angiogenesis, 
and immune modulation [22]. Clinical trials on biologics targeting various factors in IL-
6 signaling (including IL-6, IL-6R, sIL-6R, JAK, and STAT3) have shown promising 
effects in diseases including RA, systemic lupus and multiple myeloma [22]. 
TNF is extensively studied over the last 4 decades and is important in diverse 
cellular processes such as septic shock, induction of other cytokines, cell proliferation, 
differentiation, necrosis and apoptosis. The two TNF receptors TNFR1 and TNFR2 can 
be membrane bound or soluble [23]. TNFR1 is constitutively expressed in most tissues, 
while TNFR2 is inducible and typically found in cells of the immune system. Both 
receptors signal to activate the transcription factor nuclear factor kappa B (NF-țB) and 
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mitogen-activated protein kinase (MAPK) pathways inducing transcription of genes 
involved in a variety of cellular processes including inflammation, apoptosis and 
proliferation. Moreover, TNFR1 also contain a cell death domain signaling to induce 
apoptosis through caspase activation [24]. Through its receptors, TNF controls and 
orchestrates the immune response at several levels. TNF signaling is central in the 
pathogenesis of inflammatory and autoimmune diseases including RA and Crohns 
disease, and in cancer-associated chronic inflammation [24]. Overall, biologics targeting 
TNF signaling are successfully used in the treatment of chronic inflammatory disorders. 
However, adverse effects associated with global immune suppression give rise to 
concern [25].  
 
 
1.1.3. Toll-like receptors  
The initial recognition of infection by the innate immune system is best characterized in 
response to microbial infection sensed by pattern recognition receptors (PPRs) 
including TLRs [26]. TLRs are highly evolutionally conserved with high homology to 
the Toll-gene found in Drosophila melanogaster [27] and are expressed by a variety of 
cell types [28]. The first evidence of human TLR involvement in pathogen recognition 
was reported in 1997 [29]. So far, fourteen mammalian subtypes are identified of which 
TLRs 1-10 are found in humans. TLRs are exogenously located on the cell surface 
(TLR1, TLR2, TLR 4, TLR6, TLR10) or endogenously located in endocytotic 
compartments (TLR3, TLR7, TLR8 and TLR9). TLRs detect conserved microbial 
motifs known as pathogen associated molecular patterns (PAMPs). The different TLRs 
recognize and respond to structurally different PAMPs, and the subcellular localization 
correlates to some extent to the type of ligands recognized by the specific TLRs (Figure 
3). TLR2 dimerizes with TLR1 or TLR6 to discriminate between triacetylated and 
diacetylated bacterial lipoproteins, respectively. TLR6 recognizes lipipolysaccaride 
(LPS), whereas TLR5 recognizes flagellin. In contrast, the endogenous TLR3, TLR7, 
TLR8 and TLR9 are activated by nucleic acids-based PAMPs (dsRNA, ssRNA, CpG 
DNA) [28]. TLRs can also be activated by endogenous host-derived molecules in the 
absence of a microbial infection to induce “sterile” inflammation. These “self” 
molecules are referred to as danger associated molecular patterns (DAMPs) and may be 
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intracellular molecules released by necrotic cells or in response to tissue injury such as 
various proteins, fatty acids and nucleic acids. TLR2 recognizes a particularly diverse 
group of PAMPs and DAMPs due to its dimerization with TLR1 or TLR6 [28, 30].  
Although recognized as a central part of the innate immune system, TLRs are 
also important regulators of adaptive immune responses [31]. Their involvement is 
linked to a variety of pathological conditions  including inflammatory and auto-immune 
diseases such as systemic lupus, type I diabetes, inflammatory bowel disease, multiple 
sclerosis and RA [30, 32]. Moreover, TLRs are thought to contribute to the 
pathogenesis of diseases strongly associated with inflammation such as cancer and 
atherosclerosis [33, 34].  
 
1.1.4. TLR signaling pathways 
All TLRs, along with members of the IL-1 receptor family, contain a cytosolic Toll/IL-1 
receptor (TIR) domain [18]. The differential signal transduction activated upon TLR 
ligand recognition depends on recruitment of different adaptor molecules including 
myeloid differentiation factor 88 (MyD88), MyD88 adaptor-like (MAL, also called 
TIRAP), TIR-domain containing adaptor inducing IFNȕ (TRIF) and TRIF-related 
adaptor molecule (TRAM)  [35]. With the exception of TLR3, MyD88 is recruited by 
all TLRs (and members of the IL-1R family) and is essential for TLR signaling. MyD88 
further recruits the IL-1 receptor-associated kinases (IRAKs) IRAK1, IRAK2 and 
IRAK4 which leads to activation of ubiquitin ligase TNF receptor associated factor 
family 6 (TRAF6). TRAF in turn activates transforming growth factor ȕ-activated 
kinase 1 (TAK1) to phosphorylate and activate the IțB kinase (IKK) complex. IKKȕ 
phosphorylates IțB, the natural inhibitor of NF-țB. IțB phosphorylation leads to its 
ubiquitination and proteosomal degradation, allowing translocation of NF-țB to the 
nucleus to initiate inflammatory gene transcription. TAK1 can also activate members of 
the MAPK family including p38, ERK and JNK which in turn activate several 
transcription factors including AP-1 and CREB.  
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Figure 3: Schematic view of mammalian TLR signaling. TLR4, TLR5, TLR11 and the heterodimers of 
TLR2–TLR1 or TLR2–TLR6 bind to their respective ligands at the cell surface, whereas TLR3, TLR7–
TLR8, TLR9 and TLR13 localize to the endosomes, recognizing microbial and host-derived nucleic 
acids. TLR4 localizes at both the plasma membrane and the endosomes. Upon ligand recognition, TLR 
signaling is effectuated by dimerization of receptors. Engagement of the distinct signaling adaptor 
molecules stimulates downstream signaling pathways leading to the activation of the mitogen-activated 
protein kinases (MAPKs), and to activation of transcription factors nuclear factor-țB (NF-țB), interferon-
regulatory factors (IRFs), cyclic AMP-responsive element-binding protein (CREB) and activator protein 
1 (AP1). A major consequence of TLR signaling is the induction of pro-inflammatory cytokines, and in 
the case of the endosomal TLRs, the induction of type I interferon (IFN). dsRNA, double-stranded RNA; 
IKK, inhibitor of NF-țB kinase; LPS, lipopolysaccharide; MKK, MAP kinase kinase; RIP1, receptor-
interacting protein 1; rRNA, ribosomal RNA; ssRNA, single-stranded RNA; TAB, TAK1-binding 
protein; TAK, TGFȕ-activated kinase; TBK1, TANK-binding kinase 1. From O’Neill et al. 2013, with 
permission [36]. 
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These pathways can synergize in TLR-induced inflammatory gene expression by 
coordinated binding of transcription factors to AP-1 and NF-țB to binding sites found 
in the promoter sequences of several central inflammatory genes including IL-1ȕ, IL-6 
and TNF. The MyD88-independent pathway through which TLR3 and also TLR4 
mediates their signaling, TRIF is recruited to induce activation of IRF3 and the 
production of type I interferons (IFNs) which are crucial in anti-viral responses [35]. A 
schematic overview of TLR signaling is presented in Figure 3.  
 
 
1.1.5. Chronic inflammation and autoimmunity 
The purpose of the inflammatory response is to eliminate invading pathogens, repair 
damaged tissue and to restore homeostasis. Dysregulation of the inflammatory 
processes or loss of tolerance against microbes and other environmental or endogenous 
factors that do not pose a threat, may shift the acute inflammatory response towards 
becoming chronic and pathological evoking disease and tissue damage rather than repair 
and resolution. Chronic inflammation can occur when the resolution process is 
disordered. Continuous infiltration and retention of leukocytes and excessive production 
of inflammatory mediators lead to persistent inflammation and eventually tissue 
destruction [37, 38]. There is a strong link between chronic inflammation and 
tumorigenesis; the longer inflammation persists, the higher the risk of developing 
certain types of cancer [39]. Why some inflammation resolve and some do not is a 
question not yet fully answered. Our understanding of the complex signaling regulation 
leading either to perpetuation and escalation or to resolution and termination of the 
inflammatory response is expanding, but still limited. Fibroblasts are the most common 
cells in connective tissue in animals and are proposed to play a particularly important 
role in regulating the transition from an acute resolving to chronic persistent 
inflammation by regulating leukocyte behavior and function [37].  
Autoimmune diseases arise when the adaptive immune system fails to 
distinguish between “self” and “non-self” and is subsequently triggered by effectors 
(autoantibodies) produced by the host itself [40]. More than 70 different disorders 
including RA, psoriasis, systemic lupus erythematosus and multiple sclerosis are 
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categorized as autoimmune diseases, affecting approximately 5% of the Western world 
population. The immune system normally prevents self-antigens from stimulating an 
inflammatory response through a tightly regulated B-cell maturation process. The 
development of autoimmunity can occur as a consequence of a failure in B-cell 
tolerance maturation towards autoantigens, and leads to an increased number of 
circulating autoreactive B-cells [41].  
 
1.1.6. Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease affecting 
about 1% of the world’s population. RA is 2-3 times more prevalent in women than in 
men, and cause disability, chronic ill-health and premature mortality. The aetiology of 
RA, like many other autoimmune diseases, is still only partially understood, but a 
variable involvement of genetic, epigenetic and environmental factors (such as potential 
but still unproven infectious agents) are implicated [42, 43]. RA is characterized by 
chronic inflammation of the synovium – synovitis – leading to pain, swelling and 
ultimately joint destruction if untreated. Autoantibodies such as rheumatoid factor, 
antikeratin antibodies and anticirruline antibodies are detected in RA [44]. Fibroblast-
like synoviocytes (FLS) appear to be key players of the RA pathogenesis [45]. They are 
prominent drivers of inflammation through production of immunomodulating cytokines, 
chemokines and eicosanoids perpetuating inflammation and further influx of immune 
cells. Their invasive phenotype may even allow transmigration of FLS spreading RA to 
unaffected joints [46]. FLS directly contribute to joint destruction  through production 
of matrix-degrading enzymes such as matrix metalloproteinases (MMPs) degrading 
articular cartilage [47]. They also express receptor activator of nuclear factor B ligand 
(RANKL) and osteoclast differention factor. FLS may thus not only activate osteoclasts, 
but also induce osteclastogenesis and subsequent bone destruction in RA [48-50]. A 
schematic overview over the healthy versus the rheumatic joint is presented in Figure 4.  
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Figure 4: The normal versus the rheumatic joint. In healthy synovial jointsa), the synovial membrane 
lining the joint cavity is a delicate structure, only 2-3 cells deep. The synovial membrane is attached to 
skeletal tissues at the bone-cartilage interface, not connected to the surface of articular cartilage. Small 
quantities of synovial fluid (2.5 mL in a normal knee) coat the synovial surface and provide nutrition and 
lubrication to articulate free movement. In the rheumatic jointb), immune cells such as CD4+ T-helper 
cells, B cells, neutrophils and macrophages infiltrate the synovium, producing cytokines activating the 
cells of the synovial lining, the fibroblast-like synoviocytes (FLS). The synovial membrane becomes 
hyperplasic, ultimately forming an invasive and destructive structure, pannus, which migrates onto and 
into the articular cartilage and underlying bone. A continuous production of pro-inflammatory cytokines 
and chemokines along with matrix-degrading enzymes and mediators of increased osteoclast activity and 
osteclastogenesis eventually leads to destruction of cartilage and bone. From Smolen et al. 2003, with 
permission [51].  
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During the last decade, increasing lines of evidence point to involvement of TLR 
signaling in RA pathogenesis [30]. In synovium from RA patients, levels of several 
TLRs are elevated compared to osteoarthritic patients or healthy controls [32, 52]. RA 
synovial cell cultures deficient in MyD88 and TIRAP adaptor molecules display 
significantly lower spontaneous production of proinflammatory cytokines such as TNF 
and IL6 along with several MMPs [53], indicating a role for TLR signaling in synovitis. 
Several DAMPs including heat shock proteins [54-56], high mobility group box 1 
protein [57] and necrotic cells [58, 59] are detected in RA joints [60] and may thus 
contribute to TLR-induced sterile inflammation [61]. Moreover, TLR ligands of 
microbial origin, in particular bacterial peptidoglycans, are detected in RA joints [62, 
63]. In animal models, injections of TLR ligands such as peptidoglycan, CpG DNA and 
dsRNA alone induce joint inflammation [64-66]. Accordingly, TLRs may contribute to 
RA pathogenesis by recognizing both microbial and host-derived ligands found in 
arthritic joints.  
Revelation of the central roles of cytokines, TNF in particular, in RA 
pathogenesis led to the development of biological drugs targeting cytokine signaling 
networks. During the last decade, anti-TNF therapeutics such as Etanercept and 
Infliximab have been used for RA treatment with great success [25]. However, several 
drawbacks of these therapies have emerged. The degree of efficacy is inadequate as 
approximately 1/3 of patients do not respond well to treatment for unknown reasons. 
Adverse effects are associated with a global suppression of the immune system, such as 
opportunistic infections, and many patients suffer disease recurrence [25]. Accordingly, 
the search for novel therapeutic strategies is of great interest.  
 
1.2. Bioactive lipids in inflammation 
Lipids are important in our body and diet serving as source of energy, protecting our 
inner organs from injury and help us maintain stable body temperature. Moreover, cell 
membranes surrounding every single cell in our body are composed of fatty acids 
arranged in phospholipid bilayers. However, lipids are not only passive building blocks 
and energy reservoirs. Cells express hundreds of different enzymes active in the 
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biosynthesis of thousands of different lipids. The magnitude of lipid diversity is 
approaching that of proteins (10 000s); why cells invest energy into synthesizing such a 
complex lipidome is largely unclear, and we are only beginning to understand this 
diversity [67]. Many lipids are potent signal molecules regulating various biological 
processes including cell proliferation, apoptosis, metabolism and migration. 
Furthermore, bioactive lipids play pivotal roles in orchestrating initiation, perpetuation 
and resolution of the inflammatory response. The 6 fatty acid arachidonic acid (AA) is 
of particular importance as it is precursor for many bioactive lipid messengers 
regulating vital cellular processes including proliferation, apoptosis and inflammation 
(Figure 5) [68].  
Structurally and historically, bioactive lipids can be sorted into three major 
classes [69]. Class I includes eicosanoids derived from AA; prostaglandins, 
leukotrienes, thromboxanes and their relatives [70]. These lipid mediators regulate a 
wide variety of physiological and pathological processes, and are traditionally 
considered mainly pro-inflammatory. Class II represents lipid mediators with either 
glycerol or sphingosine backbone including lysophospholipids and their derivatives 
(including platelet activating factor (PAF) and sphingosine-1-phosphate [71, 72]), and 
endocannabinoids [73].  Class III consists of anti-inflammatory lipid mediators derived 
from 3 fatty acids, including resolvins and protectins derived from eicosapentaenoic 
acid (EPA)  and docosahexaenoic acid (DHA), respectively [74]. Class I, II and III lipid 
mediators generally act though recognition by their specific G-protein coupled receptors 
(GPCRs) to elicit their biological activity [75-77]. In addition, specific GPCRs are 
identified that recognize medium- to long-chained free fatty acids [78], these may hence 
be regarded as another class of lipid mediators.  
In 1893, the production of acetylsalicylic acid (launced as Aspirin) changed the 
course of anti-inflammatory therapy [79]. A new class of drugs, nonsteroidal anti-
inflammatory drugs (NSAIDs), evolved and is still one of the most widely used 
therapeutic agents today. The mechanism of action however, was not revealed until 
1971 when Sir John Vane reported the inhibitory effect of NSAIDs on the COX enzyme 
(at that time assigned the name COX1), subsequently reducing prostaglandin production 
[80]. COX enzymes are rate-limiting enzymes in the metabolism of AA to prostanoids, 
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including prostaglandins, prostacyclins and thromboxanes (Figure 5). Three COX 
enzymes are now known, COX1, COX2 and COX3 [81]. COX1 is considered to be 
more or less constitutively expressed and is found in nearly all tissues, while COX2 is 
induced by various pro-inflammatory stimuli [75]. The expression of COX2 is elevated 
in RA compared to normal and osteoarthritic synovium [82-84]. The COX3 enzyme is 
the most recently discovered and least studied of the three and its biological impact is 
still not clear. However, it has been suggested to produce anti-inflammatory members of 
the prostanoid family [85].  
Imbalances in regulating lipid signaling pathways including eicosanoids, 
lysophospholipids and lysophospholipid-related mediators such as PAF is associated 
with a wide range of pathological conditions including allergy, chronic inflammation, 
autoimmunity, cancer, hypertension, metabolic and cardiovascular diseases, among 
others [68].  
 
1.2.1. Phospholipase A2 (PLA2) enzymes  
PLA2 enzymes catalyze the hydrolysis of membrane phospholipids at the sn-2 position 
releasing a fatty acid and a lysophospholipid, which are further enzymatically 
metabolized to various lipid mediators (Figure 5). The PLA2 enzyme superfamily have 
been known and studied for more than a century, and is extensively reviewed [86-88]. 
They were first discovered and described in cobra and rattle-snake venom at the end of 
the 19th century, and later in human pancreatic extracts. To date, more than 30 enzymes 
possessing PLA2 activity are identified in mammals. They are generally divided into six 
types due to biochemical properties; secretory PLA2 (sPLA2), cytosolic PLA2 
(cPLA2), Ca2+-independent PLA2 (iPLA2), PAF acetyl hydrolase (PAF-AH), 
lipoprotein-associated PLA2 and adipose PLA2. Their diversity implicates PLA2 
enzymes in a broad range of biochemical processes and pathological conditions, in large 
part associated with their activity releasing AA as precursor of Class I bioactive lipids 
[89].  
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Figure 5: Lipid mediator pathways: PLA2 enzymes hydrolyze membrane phospholipids to release 
arachidonic acid (AA) and a lysophospholipid such as lyso-phosphatidylcholine (LPC). LPC can act as 
chemoattractant for immune cells, and can be enzymatically synthesized to form platelet activating factor 
(PAF). PAF is involved in angiogenesis, cell proliferation, osteoclastic bone resorption and inflammation. 
AA is metabolized through cytochrome P-450 (CYPP450), lipoxygenase (LOX) pathways or 
cyclooxygenase (COX) pathways to form bioactive eicosanoids including leukotrienes (LTs), lipoxins 
(LXs) and prostanoids including prostaglandins (PGs), prostacylins (PGIs) and thromboxans (TXs). 
Prostanoids are generally pro-inflammatory increasing vascular permeability and immune cell 
chemotaxisis, angiogenesis, adhesion and cell growth, whereas lipoxins exert anti-inflammatory effects. 
TXs facilitate platelet aggregation, while PGI2 prevents platelet aggregation. Non-steroidal anti-
inflammatory drugs (NSAIDs) inhibit COX enzymes, blocking the production of pro-inflammatory 
eicosanoids. Lipid mediators act through their specific G-protein coupled receptors (GPCRs) on target 
call membranes. Modified from Harizi et al. 2008 [70] and Murakami 2011 (60) with permission. 
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1.2.1.1. Cytosolic phospholipase A2  
cPLA2s (group IV cPLA2) are large, cytosolic proteins (61-114 kDa) typically 
containing a C2 domain for Ca2+-dependent association to the membrane [90]. The first 
identified cytosolic PLA2, now attributed to group IVA PLA2 (cPLA2Į), was reported 
by Christina Leslie and Ruth Kramer in 1986 in neutrophils [91] and platelets [92], 
respectively. The cPLA2Į enzyme and later purified, sequenced and cloned by James 
Clark and Ruth Kramer in 1991 [93, 94]. Since then, six cPLA2 subtypes are identified 
[86], but cPLA2Į is still the most extensively studied isoform. cPLA2Į is regulated by 
an increase in intracellular Ca2+ levels and by phosphorylation in response to various 
cellular stimuli [95]. The cPLA2Į enzyme contains several important phosphorylation 
sites, including Ser505, Ser727 and Ser515. These sites are phosphorylated by mitogen-
activated protein kinases (MAPKs), MAPK-interacting kinase (MKK1), and calcium-
calmodulin kinase II, respectively [90]. In general, Ca2+-binding induces translocation 
of cPLA2Į to intracellular membranes including Golgi, ER and the nuclear envelope, 
while cPLA2Į phosphorylation plays an important role in regulating catalytic activity 
releasing AA from membrane phospholipids [90]. 
Unlike other PLA2 enzymes, cPLA2Į possesses acyl chain specificity for AA in 
vitro [93, 96, 97]. Due to its central role in AA release and subsequent eicosanoid 
production, cPLA2Į activation is considered important in regulating normal and 
pathological processes in various tissues and cell types [98-100]. Studies in cPLA2Į 
deficient mouse models and human cell cultures have indicated a role for cPLA2Į in 
inflammatory diseases including collagen-induced arthritis [101, 102], asthma [103], 
pulmonary fibrosis [104], Parkinson [105] and other neurodegenerative diseases [106], 
and also in tumorigenesis [107, 108]. Accordingly, cPLA2Į is proposed to be a 
potential therapeutic target in the treatment of inflammatory disease; however, the 
molecular mechanisms involved are still not elucidated. More research is needed to 
survey the processes in which cPLA2Į activity is implicated, and downstream cellular 
effects of its inhibition. 
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1.2.1.2. Calcium-independent phospholipase A2 
The Ca2+-independent PLA2s (iPLA2s) have structural similarities with cPLA2, and 
these two types of enzymes are believed to have evolved from a common ancestral gene 
[87]. The iPLA2 enzyme was first characterized in macrophages in 1994 [109]. Since 
then, six human iPLA2 members are identified, diverse in structure and function [86]. 
Although GII, GIVC and GVIII all are display Ca2+-independent activity, the term 
“iPLA2” only apply to GVI PLA2. iPLA2s activity is associated with processes 
including proliferation, apoptosis, bone formation and monocyte recruitment. iPLA2s 
are further believed to function as “house-keeper” enzymes  maintaining lipid and 
membrane homeostasis within cells [86, 110]. iPLA2s lack substrate specificity, and 
can thus release a variety of fatty acids in addition to AA [111], including DHA, a 
precursor of resolvins involved in resolution of inflammation [112]. The iPLA2 
enzymes are also associated with several pathological conditions, including diabetes, 
Barth syndrome and neurodegenerative disorders [86]. 
 
1.2.1.3. Secretory phospholipase A2 
sPLA2s are low-molecular mass, Ca2+ requiring enzymes initially described in snake 
and bee venoms [113]. The purification and cloning of the first human, non-pancreatic 
secreted PLA2 in 1988 (designated type IIA secretory PLA2), more resembling the 
PLA2s known from rattlesnake venom than the known human pancreatic PLA2s, 
caught the eye of a broader scientific community [114, 115]. The human genome 
contains nine sPLA2 genes encoding catalytically active enzymes comprising PLA2 
groups I, II, V, X and XII [86]. sPLA2s exhibit a large variety of cellular functions and 
their expression pattern vary greatly with cell type and tissue location. Central functions 
of sPLA2s are their role in host defense against bacterial infection due to their ability to 
kill gram-positive and Gram-negative bacteria [116], and their antiviral activity [117]. 
The sPLA2s also appear to be implicated in various inflammatory diseases [86]. Several 
sPLA2 isoforms are expressed and released by human immune cells including 
macrophages, monocytes, neutrophils, mast cells and T-cells. Elevated levels of various 
isoforms are detected at sites of inflammation, and in biological fluids and tissues from 
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persons with inflammatory or auto-immune diseases such as acute pancreatis [118], 
septic shock [119], inflammatory bowel disease [120] and RA [114, 121, 122].  
 Together with cPLA2Į, sPLA2s are considered the primary PLA2s catalyzing 
AA release [123, 124] although iPLA2s can also contribute [125]. However, the 
catalytic effects of sPLA2 are not limited to AA release but may also include other 
unsaturated fatty acids such as oleic acid, linoleic acid and 3 fatty acids (e.g. DHA and 
EPA, precursors of anti-inflammatory lipid mediators) [87]. The involvement of sPLA2 
in the inflammatory response was initially believed to be in large part due to hydrolysis 
of AA as a substrate for the biosynthesis of proinflammatory lipid mediators. However, 
during the last decades alternative mechanisms for sPLA2s to activate immune cells and 
to induce production of inflammatory mediators have been identified [126]. These 
mechanisms are believed to be unrelated to the catalytic activity of sPLA2 and rather 
due to interaction to specific or promiscuous receptors or surfactant protein on cell 
membranes [127].    
 
1.2.2. Platelet-activating factor 
PAF (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) was first described in 1972 to 
induce  platelet aggregation and histamine production in rabbit basophils [128]. PAF 
can be synthesized via de novo or remodeling pathways; de novo synthesis provides 
small physiological amounts of PAF for normal cell function, whereas the remodeling 
pathway is believed to be the primary route of PAF synthesis in response to pro-
inflammatory stimuli and stresses such as UV-radiation [129, 130]. PAF is not stored, 
but is rapidly synthesized in response to stress. cPLA2Į is a key enzyme in the 
remodeling pathway of PAF synthesis as demonstrated in independent knock-out 
animal models [103, 131]. cPLA2Į activity removes the sn-2 residue of 
phosphatidylcholine, leaving a molecule of lyso-PAF which is further metabolized to 
biologically active PAF (Figure 5) [132]. Moreover, PAF is in turn a potent inducer of 
PLA2 activity and subsequent AA release, creating a positive feed-back loop [133-135]. 
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PAF signals through the PAF receptor (PAFR) which is expressed on the cell 
surface of a wide variety of cells [135]. Signaling mediated downstream the PAFR 
include activation of phospholipases PLA2, PLC and PLD, protein kinase C, 
phosphatidylinositol 3-kinase, protein tyrosin kinases, MAPKs and the second 
messengers inositol triphosphate, diacylglycerol, calcium and cyclic adenosine 
monophosphate (cAMP) [135]. In addition, PAFR independent signaling can also occur 
[136]. Through its downstream mediators, PAF can activate transcription factors 
including AP-1 and NF-țB, leading to transcription of inflammatory genes [137-139]. 
PAF is considered a potent mediator of the inflammatory process [140], and elevated 
levels of PAF is reported in inflammatory diseases such as Crohns disease [141], 
psoriasis [142], ischemic injury [143] and asthma [144]. However, its name is today 
somewhat misleading since PAF elicits a variety of physiological and pathological 
actions besides acting as a pro-inflammatory lipid messenger [145]. PAF is associated 
with apoptosis [146], cell proliferation [147],  reproduction [148], osteoclastic bone 
resorption [149], tumor growth, metastasis and angiogenesis [150, 151], and beneficial 
effects of blocking the PAFR is shown in several types of cancer including breast 
cancer and melanoma [152]. PAF is also proposed to be involved in keratinocyte 
proliferation and wound healing [153, 154].  
PAF is deactivated by a group of PLA2 enzymes, PAF-AH, and the degradation 
of PAF by PAF-AH is demonstrated  to inhibit severe acute inflammation [155]. A 
decreased plasma level of PAF-AH is associated with several diseases including asthma 
[156], systemic lupus erythematosus [157], juvenile RA [158] and Crohn’s disease 
[159]. These observations indicate a harmful effect of an increase in pathological levels 
of PAF as a consequence of reduced PAF-AH activity. In contrast, detection of elevated 
PAF-AH levels are reported in pathological conditions associated with inflammation 
including RA [160] and diabetes [161]. Moreover, exogenous (recombinant) PAF-AH is 
recently shown to play a central role in reducing inflammatory injury and clearance of 
bacteria in a murine model of sepsis [162]. This may represent a defensive strategy to 
compensate for elevated levels of PAF induced by the inflammatory process [163]. 
Indeed, PAF-AH is secreted by hematopoietic cells in response to pro-inflammatory 
stimuli [164], and PAF-AH display neuroprotective properties in mouse ischemia [165].  
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1.2.3. Prostaglandin E2 
PGE2, synthesized from AA by the COX enzymatic pathway, is the most abundant 
prostaglandin and has been recognized as a biologically active immunoregulator since 
the 1960s [166]. Its biological effects are ubiquitous in both physiological and 
pathophysiological mechanisms including nerve growth, nerve and brain functions, 
wound healing, bone metabolism, fever, pain and immune responses, and is associated 
with diseases including Alzheimer’s disease, RA and cancer [69, 167]. The central role 
of PGE2 in inflammation is emphasized by the effective symptomatic relief by NSAIDs 
in patients suffering from chronic inflammation such as RA [168], which is in large part 
attributed to reduced PGE2 synthesis [69]. PGE2 is a known immunoactivator [169], 
and promote immune cell influx to inflamed tissues and inflammatory angiogenesis 
[170, 171]. In the joint, PGE2 is shown to mediate chronic joint inflammation in 
collagen-induced arthritis (CIA) in mice [172] and CIA mice deficient in mPGES-1, the 
enzyme converting PGH2 into PGE2 (Figure 5), display reduced disease activity [173]. 
PGE2 is also shown to induce inflammatory gene expression in RA synovial fibroblasts 
[174]. PGE2 is furthermore proposed to be a critical factor in bone and cartilage 
resorption in arthritis through regulation of osteoclast activity and expression of 
cytokines and MMPs in various model systems [175-177]. However, the actions of 
PGE2 are highly pleiotropic. PGE2 can also exert anti-inflammatory and 
immunosuppressive effects, possibly dependent on the cell type and receptor subtypes 
involved [167, 178-180]. Furthermore, PGE2 can act in concert with other prostanoids 
to modulate inflammation in a context-dependent manner to shift the whole process in 
both anti-inflammatory and proinflammatory directions [181]. 
PGE2 signals through four substrate-specific GPCRs; EP1, EP2, EP3 and EP4 
[181]. EP2 and EP4 increase intracellular cyclic AMP (cAMP) levels inducing protein-
kinase A activation, while EP3 decreases cAMP levels. The effects of PGE2 are 
believed to be cell- and tissue specific due to this receptor diversity, receptor 
distribution and pathway cross-talk. EP3 exists in several splicing variants, and may 
thus constitute a key to the pleiotrophic effects attributed to PGE2 [182]. EP receptors 
can also transactivate the epidermal growth factor receptor (EGFR) and downstream 
signaling cascade [183, 184]. In addition, PGE2 is recognized by nuclear receptors 
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including peroxisome proliferator activated receptors (PPARs) [185]. This diversity in 
receptors, variability in their expression and pathway cross-talk may explain why one 
mediator like PGE2 can elicit such pleiotropic responses. 
 
2. Study objectives  
Chronic inflammatory diseases represent a major challenge and are a common cause of 
decreased life quality and premature mortality. However, the aetiology of many 
autoimmune and chronic inflammatory diseases (including RA and psoriasis) is still 
largely unknown, and the therapeutics available are associated with adverse effects and 
unsatisfactory efficacy. The inflammatory response involves many different cell types, 
and a finely tuned production of pro-inflammatory, anti-inflammatory and resolving 
mediators. The shift from a beneficial well-regulated inflammation resulting in 
resolvation and tissue repair towards a pathological chronic inflammation can be 
triggered by small imbalances in this highly complex signaling network. Bioactive 
lipids and enzymes catalyzing their biosynthesis are becoming increasingly interesting 
as our understanding of their roles orchestrating inflammation and immune responses 
expands. In order to understand the pathology of chronic inflammatory diseases and to 
develop novel therapeutic strategies, it is of crucial importance to understand the 
molecular signaling mechanisms and relationships between cells, processes and 
signaling pathways involved. 
The overall objective of this work was to investigate the role of cPLA2Į and 
lipid messengers in molecular mechanisms involved in chronic inflammatory disease. 
As this thesis emerged from the substantial research performed by Berit Johansen and 
the PLA2 research group concerning involvement of PLA2 enzymes in cellular 
signaling mechanisms typical for psoriasis, the role of PAF was investigated in a 
keratinocyte model system (Paper I). We next established a cellular model system for 
RA, directing our focus towards investigating the role of PLA2 enzymes, cPLA2Į in 
particular, in central signaling pathways relevant for chronic joint inflammation (Papers 
II-IV).   
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The aims of this thesis were as follows: 
 
Aim 1: To elucidate the cellular consequences of PAF stimulation – what is the pre-
dominant role of PAF in differentiated keratinocytes? (Paper I). 
Aim 2: To investigate the involvement of cPLA2Į enzyme activity in TNF-induced 
signaling in synoviocytes (Paper II). 
Aim 3: To investigate the involvement of cPLA2Į and possibly other PLA2 subtypes in 
TLR2-induced signaling (Paper III). 
Aim 4: To investigate involvement of MAPKs in TLR2-induced cPLA2Į activation, 
and whether NF-țB is implicated in TLR-induced, cPLA2Į-dependent cytokine 
production.  
Aim 5: Can COX-derived prostanoids, such as PGE2, act as messengers downstream 
cPLA2Į activity in regulating TLR2 signaling? (Paper IV). 
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3. Summary of papers 
Paper I 
Platelet-activating factor (PAF; 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a 
phospholipid-derived signaling molecule with highly pleiotrophic effects. PAF is 
believed to be implicated in several pathological conditions including psoriasis, 
inflammation and allergy, and may also participate in mitogenic events and cancer 
development. Increased levels of PAF are found in psoriatic skin, but PAF’s exact role 
in epidermis is uncertain. In paper I, we aimed to investigate the physiological 
consequences of excess PAF production in epidermis. We examined the gene regulatory 
effects of PAF short-term stimulation in differentiated HaCaT keratinocytes by 
transcriptional profiling. Even though PAF induces COX2 expression, we found that 
PAF regulates only few genes associated with inflammation in differentiated 
keratinocytes. Rather, we show that natural PAF rapidly regulates genes involved in 
proliferation, (anti)-apoptosis and migration, all sub-processes of re-epithelialization 
and wound healing. Moreover, profiling of phosphorylated kinases, cellular wound-
scratch experiments, resazurin assay and flow cytometry cell cycle phase analysis all 
support a role for PAF in keratinocyte proliferation and epidermal re-epithelialization. 
In conclusion, these results suggest that PAF acts as an activator of proliferation and 
may, therefore, function as a connector between inflammation and proliferation in 
differentiated keratinocytes. 
 
 
Paper II 
Rheumatoid arthritis (RA) is an inflammatory joint disease characterized by chronic 
synovitis causing pain, swelling and loss of function due to destruction of cartilage and 
bone. The complex series of pathological events occurring in RA are largely regulated 
via excessive production of pro-inflammatory cytokines, the most prominent being 
tumor necrosis factor (TNF). The objective of this work was to elucidate the 
involvement of group IVA cytosolic phospholipase A2 (cPLA2Į) in TNF-induced 
regulation of synovitis and joint destructive effectors in synoviocytes (synovial 
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fibroblast-like cells), as a cellular model system for RA synovium. Inhibitors of 
cPLA2Į enzyme activity (AVX002, ATK) significantly reduced TNF-induced cellular 
release of AA, PGE2, IL8 and MMP3. This reduction was evident both at 
transcriptional, protein or metabolite levels. Interestingly, cPLA2Į inhibition affected 
several key points of the arachidonyl cascade; AA-release, cyclooxygenase-2 (COX2) 
expression and PGE2 production. Furthermore, our results suggest that cPLA2Į is 
subject to transcriptional auto-regulation as inhibition of cPLA2Į resulted in reduced 
PLA2G4A gene expression in TNF-stimulated synoviocytes. Thus, cPLA2Į appears to 
be an important regulator of central effectors of inflammation and joint destruction, 
namely MMP3, IL8, COX2, and PGE2. Decreased transcription of the PLA2G4A and 
COX2 genes in response to cPLA2Į enzyme inhibition further suggest a self-reinforcing 
effect of cPLA2Į inhibition in response to TNF. Collectively, these results suggest that 
cPLA2Į is a modulator of synovitis as its inhibition reduces the production of multiple 
key pro-inflammatory factors involved in RA pathogenesis. 
 
Paper III 
In rheumatoid arthritis (RA), toll-like receptors (TLRs) contribute to synovitis by 
recognizing damage-associated molecular patterns (DAMPs) or pathogen-associated 
molecular patterns (PAMPs) found in RA joints. Studies in cell cultures, animal models 
and clinical trials point to TLR2 as a driver of synovial inflammation and joint 
destruction in RA. However, few studies have investigated the implication of PLA2 
activity in TLR-induced signaling in RA synovium. Having shown the involvement of 
cPLA2Į activity in TNF-induced synoviocyte inflammatory and joint-destructive 
mediators, we now aimed to characterize PLA2 enzyme involvement in TLR2-induced 
signaling. TLRs1-7 and a range of sPLA2, iPLA2 and cPLA2 enzymes were found to 
be transcriptionally expressed in cultured synoviocytes. Activation of TLR2/1 and 
TLR2/6 led to phosphorylation of cPLA2Į at Ser505, and induced AA release and PGE2 
production; effects that were attenuated by cPLA2Į inhibitors. In contrast, sPLA2 
inhibitors did not affect AA or PGE2 release. cPLA2Į inhibitors furthermore attenuated 
TLR-induced expression of IL-6, IL-8 and COX2. Our results demonstrate for the first 
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time that cPLA2Į is involved in TLR2/1- and TLR2/6-induced AA release, PGE2 
production and pro-inflammatory cytokine expression in synoviocytes. As a modulator 
of TLR2 signaling, our results expand the understanding of cPLA2Į as a regulator of 
inflammatory molecular mechanisms in synoviocyte signaling. 
 
Paper IV 
In Paper III, we show that cPLA2Į acts downstream the TLR2/6 ligand FSL-1 in 
regulating AA release, PGE2 production and IL-6 protein levels in human synoviocytes. 
Here, we aimed to investigate this signaling pathway in more detail. We found MAPKs 
p38 and ERK1/2 to be involved in FSL-1-induced cPLA2Į phosphorylation at Ser505, 
and in subsequent AA release and PGE2 production. Inhibition of cPLA2Į further 
attenuated FSL-1-induced IțBĮ degradation, as did cyclooxygenase (COX) inhibition, 
indicating a role for both cPLA2Į and COX-derived eicosanoids in regulating TLR2-
induced NF-țB activation and hence subsequent transcription of NF-țB-regulated IL-6. 
Indeed, COX inhibition attenuated FSL-1-induced IL-6 transcription and protein 
production comparable to cPLA2Į inhibition. Moreover, exogenously added PGE2 
alone induced IL-6 production and completely rescued IL-6 transcription when added 
simultaneously with FSL-1 in the presence of a cPLA2Į inhibitor. Collectively, these 
results provide novel insights into the mechanism that cPLA2Į, activated by p38 and 
ERK1/2, regulates TLR2-induced NF-țB activation and IL-6 production, possibly 
through COX/PGE2-dependent pathways.  
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4. General discussion 
Diving into the world of lipid signaling is fascinating, challenging, at times confusing 
and provoke an intriguing admiration for the exquisitely fine-tuned regulation essential 
for our well-being. The inflammatory response and our immune system involve cross-
talk between many signal-transduction pathways. Lipolytic enzymes (i. e. enzymes 
catalyzing the hydrolysis of lipids) and bioactive lipids have emerged as signaling “hot-
spots” orchestrating many of these immunological processes and the shift between a 
normal, resolving inflammation towards a chronic pathological inflammation. However, 
the complexity of lipid signaling and cellular consequences of their actions is not fully 
elucidated. Lipid signaling is complex, redundant and often interconnected and even 
counter-regulated. In order to develop future therapeutic strategies and pin-point novel 
therapeutic targets in chronic inflammatory disease, we need to understand these 
underlying signaling mechanisms and pathway interactions.   
A detailed discussion concerning the significance of our results in relevance to 
the specific model systems and inducers are discussed in detail in the respective papers. 
In this general discussion I will first briefly address the main findings in Paper I with 
focus on PAF-mediated effects in keratinocyte proliferation and wound healing (Aim 
1). Next, Papers II-IV will be discussed in view of joint inflammation and RA, and the 
overall significance of our findings (Aims 2-5). The discussion will then be more 
generalized towards addressing the question of bioactive lipids as connectors between 
inflammatory and proliferative processes, in light of our findings in Papers I-IV. 
Finally, the future of cPLA2Į as a potential therapeutic target will be discussed. 
 
4.1. PAF - a promotor of proliferation and epidermal wound healing  
Traditionally, PAF is considered a pro-inflammatory mediator, and is elevated in 
psoriatic scale [142] and dermatitis [186]. Expression of PAFR is also elevated in 
psoriatic lesions compared to normal skin [187], indicating a role for PAF in psoriasis 
pathogenesis. However, as described in Paper I we found few indications of a pro-
inflammatory role of PAF in differentiated keratinocytes. Our results rather suggest that 
PAF primarily signal to induce transcription of genes associated with increased mitotic 
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activity, survival and migration, and that PAF promotes a re-entry of differentiated 
keratinocytes into a proliferative state; all mechanisms important in epidermal wound 
healing. The process of wound repair and tissue regeneration is characterized by 
inflammation including infiltration of immune cells, angiogenesis, re-epithelization and 
tissue remodeling [10]. Lipid mediators such as eicosanoids, endocannabinoids and 
sphingolipids play critical roles in regulating wound healing and tissue repair through 
modulation of the inflammatory process [11]. The role of PAF in regulating 
proliferative responses in keratinocytes is not unknown; in transgene keratinocytes 
expressing PAFR, accelerated proliferation was induced [147], and PAFR activation 
can induce proliferative effects through cross-talk with EGFR signaling [153]. 
However, there has been contradictory reports suggesting  anti-proliferative effects of 
PAF/PAFR signaling [154]. As discussed in detail in Paper I, our results indicate that 
the proliferative effects of PAF are differentiation-dependent, thus providing a possible 
explanation for these contradictory findings. As PAF is produced in the initial 
inflammatory phase of wound healing, our results suggest that PAF/PAFR signaling 
links the inflammatory and proliferative processes, thus representing interesting 
therapeutic targets regarding impaired wound healing and pathological 
hyperproliferation such as dermatoses and cancer. 
In RA, hyperproliferation of the synovial membrane is a hallmark. Little is 
known about the role of PAF in the joint, but levels of PAF are elevated in the synovial 
fluid of RA patients compared to osteoarthritic patients [188]. PAF is assigned a pro-
inflammatory role in animal models of arthritis, as a PAFR antagonists display anti-
inflammatory effects and reduced cartilage destruction [189, 190]. In osteoarthritic 
chondrocytes, PAF can activate both AA selective and non-selective  PLA2 enzymes 
[191]. Unpublished data from our lab show that synoviocytes respond rapidly and 
strongly to PAF stimulation, both by increased AA release and by the transient 
morphology change described in Paper I. These responses in synoviocytes are induced 
by even lower PAF concentrations than in keratinocytes. There are no reports 
investigating a role of PAF in the in inflammatory synovial hyperproliferation; based on 
our findings, a possible proliferative effect of PAF in RA synovium is an interesting 
hypothesis to be addressed in future studies. Moreover, as PAF is both a product of, and 
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an activator of cPLA2Į activity, it would be of interest to investigate the impact of 
cPLA2Į inhibition on PAF production, and subsequent cellular consequences. 
 
4.2. cPLA2Į as a regulator of synovial inflammation and joint destruction 
PLA2 enzymes along with other lipolytic enzymes metabolizing lipid mediators from 
AA or lysophospholipids have received increasing attention during the last decades and 
are highly relevant in the search for novel therapeutic approaches in treating 
inflammatory disorders. Lipid mediators generated downstream cPLA2Į activation 
gives rise to a diversity of responses, many of which are pro-inflammatory and 
associated with various chronic inflammatory and autoimmune diseases as described 
introductory. Several groups have reported a pathologic role of cPLA2Į in murine 
models of inflammatory arthritis [101, 102, 192], and ameliorating effect of chemical 
cPLA2Į inhibition [193, 194]. However, the underlying mechanisms are yet to be 
elucidated. Synovitis and synovial hyperplasia are key features of RA and FLS derived 
from RA joints display an aggressive hyperproliferative phenotype, producing a variety 
of cytokines, chemokines and matrix-degrading enzymes driving synovitis and joint 
destruction [47]. Accordingly, FLS are considered key players in RA pathogenesis 
driving synovitis and joint destruction [45]. In Papers II-IV we applied the synovial 
fibroblast cell line SW982 (originating from a synovial sarcoma) as model system for 
RA synovium [195]. Fibroblasts in general are believed to play a key role in the 
development of chronic persistent inflammation [38, 196], and quiescent fibroblasts (as 
experimentally used in these studies) are shown to be particularly responsive to pro-
inflammatory stimuli, hence providing a useful tool to study these signaling 
mechanisms [197].  
In order to investigate the orchestrating role of cPLA2Į in RA joint 
inflammation, we focused on two central pro-inflammatory stimuli; TNF and TLR2 
activation. The central role of cytokines, particularly TNF, in inflammation is well 
documented, and TNF-blocking biologics are widely used in the treatment of RA along 
with other inflammatory diseases including psoriasis, psoriatic arthritis, ankylosing 
spondylitis, and Crohn’s disease [25]. TLRs are important regulators of both innate and 
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adaptive immune responses, and dysregulation of their activation has emerged as an 
important factor in inflammatory and autoimmune diseases including, asthma, systemic 
lupus erythematosus (SLE) and RA [198]. Expression levels of several TLRs including 
TLR2 are elevated in RA [50, 52] and in particular at sites of cartilage destruction 
[199].  Moreover, several PAMPs and DAMPs known as TLR2 or TLR2-heterodimer 
ligands are found in RA joints [56, 60, 62]. Thus, the TLR2/1 and TLR 2/6 ligands 
Pam3CSK4 and FSL-1 were selected for the initial investigations presented in Paper III. 
Investigating the involvement of PLA2 enzymes and lipid messengers in TNF- and 
TLR2- induced signaling in synoviocytes as is done in Papers II-IV can provide 
valuable insights into important molecular mechanisms in RA pathogenesis. As we 
aimed to investigate the signaling downstream TLR2 activation in more detail in Paper 
IV, FSL-1 was selected due to its more potent induction of AA release.  
cPLA2Į is a key enzyme in synoviocyte AA release and subsequent PGE2 
production in response to both TNF (Paper II) and TLR2 activation (Paper III). Our 
results further suggest that cPLA2Į regulate TNF and TLR2-induced COX2 
transcription; thus possibly affecting PGE2 synthesis both directly through providing 
AA as substrate for biosynthesis, and indirectly by regulating expression of the COX2 
enzyme which is rate-limiting in PGE2 biosynthesis [75]. Transcriptional regulation of 
COX2 by cPLA2Į has previously been shown in murine model systems [194, 200], 
supporting our data.  
In Paper II we found that inhibition of cPLA2Į attenuated its own transcription 
in response to TNF. The promoter region of the PLA2G4A gene contains binding sites 
for NF-țB, and cPLA2Į is produced in response to IL-1ȕ-induced NF-țB activation 
[201]. In Paper IV, we found cPLA2Į to regulate NF-țB transcriptional activity, a 
mechanism also reported in other cell types [100, 202-204]. Our results may thus 
suggest that activated cPLA2Į can stimulate its own transcriptional expression in a 
feedback-loop involving NF-țB in response to cytokines and possibly TLR2 activation. 
Together, our data propose that inhibition of cPLA2Į activity may have a self-
reinforcing effect on AA release and subsequent PGE2 production through negatively 
regulating both COX2 and cPLA2Į expression.  
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In Papers III-IV we investigate the involvement of cPLA2Į in TLR2-induced 
IL-6 expression. IL-6 is proposed to play a role in the shift from acute towards chronic 
inflammation [205] and is involved in synoviocyte activation, driving synovitis and 
joint destruction in RA [206, 207]. Increased levels of IL-6 are detected both in the joint 
and systemically in RA patients [208, 209] and experiments from various model 
systems support a pathological role for IL-6 in RA [210]. IL-6 deficiency provides 
protection against development of murine CIA [211, 212], and anti-mouse IL-6 
monoclonal antibody suppress CIA development [213]. In humans, anti-IL-6 therapy 
improves symptoms of RA [198, 206, 214]. Our results demonstrating that synoviocyte 
IL-6 levels is partly controlled by cPLA2Į in response to TLR2 activation, further 
support a role for cPLA2Į as a central regulator of molecular mechanisms in synovial 
inflammation. 
Our results in Papers II-IV clearly demonstrate that cPLA2Į inhibition potently 
reduces PGE2 levels, which, considering the pleiotropic roles of PGE2 in RA and 
inflammation in general, indicate a potential anti-inflammatory effect. Our results 
further indicate that PGE2 may be an important actor downstream cPLA2Į in regulating 
at least TLR2-induced IL-6 levels. This mechanism is to our knowledge not previously 
described in synoviocytes. Moreover, as NF-țB is central in inflammation in general 
and RA in particular [215, 216], our finding that cPLA2Į can modulate synoviocyte 
NF-țB activation, possibly through COX/PGE2, is important expanding our 
understanding of the molecular mechanisms regulated downstream cPLA2Į activity. 
 Degradation of cartilage and bone is a hallmark of RA. Of the metabolites we 
found regulated by cPLA2Į activity (Papers II-IV), several are known to be involved in 
RA joint destruction. MMP3, with its wide range of substrate specificity and ability to 
activate other MMPs, is essential in RA cartilage degradation [217-219]. Osteoclasts are 
the main cells mediating focal bone erosion in RA. PGE2 is proposed to be a central 
factor in bone and cartilage resorption in arthritis through regulation of osteoclast 
activity and expression of cytokines and MMPs in various model systems [175-177]. 
IL-6 is implicated in  osteoclast differentiation through its soluble receptor sIL-6R 
[220], possibly in cross-talk with PGE2 signaling as reported in murine osteoclast cell 
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cultures [221]. Our results thus suggest that cPLA2Į regulates the expression of 
metabolites involved in RA joint destruction.  
cPLA2Į is proposed to be a regulator of neutrophil recruitment in murine CIA 
[192]. In Paper II, we show that cPLA2Į is involved in TNF-induced production of the 
chemokine IL-8 which is overexpressed in RA synovium and acts as a chemoattractant 
for neutrophils [222, 223]. This finding suggests a possible mechanism through which 
cPLA2Į may affect neutrophil recruitment in RA. Furthermore, IL-8 acts as an 
angiogenic factor. Angiogenesis, the formation of new blood vessels, is crucial in many 
physiological processes including reproduction, development and tissue repair [224]. In 
RA, along with many other pathologic condition including obesity, cancer and psoriasis, 
the angiogenetic process is dysregulated and excessive formation of new blood vessels 
is important in disease development [225]. Along with IL-8, COX2 and PGE2 are 
described as actors in the angiogeneic process [226]. Also IL-6 is shown to promote 
angiogenesis in RA [227]. Our results presented in Papers II and III demonstrate a 
regulatory role for cPLA2Į in the production of all of these factors, thus indicating a 
role for cPLA2Į in modulating synovial angiogenesis.   
To sum up, our findings in Papers II-IV suggest that cPLA2Į hold a key position 
in synoviocytes regulating pro-inflammatory, angiogenetic and joint destructive 
signaling downstream TNF and TLR2 activation, both important pathological signaling 
pathways involved in RA pathogenesis.  
 
4.3. cPLA2Į and bioactive lipids – links between chronic inflammation and 
cancer 
The association between inflammation and cancer was first proposed in 1863 by Rudolf 
Virchow who noted that tumors tended to develop at sites of chronic inflammation 
[228]. Today, a substantial and growing amount of data reveals the importance of 
inflammatory processes in cancer initiation and progression [229]. Chronic 
inflammation predisposes to a variety of cancers, and 15-20% of all cancers worldwide 
are estimated to origin from underlying infections and inflammatory responses [228]. 
There are two pathways by which inflammation and cancer are viewed to be linked; 
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extrinsic pathways where smouldering inflammation increase cancer risk, and intrinsic 
pathways where dysregulated activity of oncogenes or tumor-suppressor genes causes 
inflammation and tumor development [230]. The body’s response to tumors have many 
similarities with a healing wound; following tissue damage, cell proliferation is 
enhanced while the tissue regenerates. When the repair is complete or the assaulting 
agent is removed, inflammation and proliferation recede to resume tissue homeostasis. 
In tumors, like in impaired wound healing, this resolution fails and cells continue 
proliferating in an environment rich in inflammatory cells secreting inflammatory 
cytokines and growth/survival factors. In that sense, tumors resemble wounds that fail 
to heal [231]. 
In Paper I, we investigated the effects of PAF in keratinocytes, primarily 
revealing proliferative rather than pro-inflammatory responses, presumably directing 
cell signaling towards keratinocyte dedifferentiation, wound-healing and tissue repair. 
However, these findings may also suggest PAF as a link between inflammation, 
hyperproliferation and possibly even cancer development. PAF is indeed detected in 
elevated levels in colorectal carcinoma [150]. Furthermore, PAF regulates vascular 
endothelial cell migration and invasion [232], and is proposed to contribute to tumor 
growth in breast cancer [151] and prostate cancer [233] through enhanced cell motility 
and proliferation. PAF is also found to be a potent promotor of tumor angiogenesis 
[152] and is attributed a promoting role of skin melanoma metastasis [152, 234, 235]. In 
support of its role in skin cancer, PAFR transgenic mice display progressive 
hyperproliferative changes in the epidermis [147]. Inhibiting the PAFR furthermore 
efficiently inhibits proliferation of breast cancer cells [236]. Our results in Paper I 
revealing novel aspects of PAF-induced cellular responses in differentiated 
keratinocytes may thus complement the understanding of PAF as a regulator of 
hyperproliferation, cell migration and possibly tumorigenesis. However, psoriasis, 
although a chronic inflammatory disease, is rarely, if ever, accompanied by skin cancer 
[237]. This illustrates that our understanding of the inflammatory process and links to 
cancer development is still incomplete.  
PAF is only one of many lipids generated downstream cPLA2Į activation 
implicated in proliferative responses and tumorigenesis. Prostanoids play important 
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roles also in proliferation and tissue regeneration [11]. PGE2, PGF2Į and TBX2, three 
main products of the COX enzymatic pathway, are proposed to be implicated in prostate 
cancer tumorigenesis through regulating proliferation, angiogenesis, metastasis and 
invasion [238-240]. PGE2 levels in particular are elevated in human tumors and is 
associated with regulation of leukocyte function, increased angiogenesis, metastasis, 
survival responses and cell cycle regulation [167, 241-243]. Accordingly, NSAID 
treatment is associated with decreased initiation and progression of tumorigenesis, and 
thus reduced mortality in several cancer types, including colorectal cancer [244-246]. 
Also in murine cancer models, COX enzymes appear to play crucial roles in tumor 
development and progression [247]. In view of the significance of COX enzymes and 
eicosanoids in development of many human cancers, it is not surprising that cPLA2Į, a 
major provider of AA substrate for COX enzymes, is suggested to be implicated in 
tumorigenesis [108]. Several studies in murine models of cancer have pointed to a role 
for cPLA2Į in tumor development and progression [107, 247-250]. The mechanisms by 
which cPLA2Į impacts tumor growth are not fully understood, but regulation of tumor 
angiogenesis is proposed as a central factor [107, 251]. Having found cPLA2Į to 
regulate multiple angiogenetic factor in synoviocytes, our results may contribute to the 
understanding of cPLA2Į as an angiogenetic modulator. 
Besides serving as a key enzyme in AA release and PGE2 production, we found 
cPLA2Į to regulate expression of IL-6, IL-8, and MMP3. In addition to playing 
important roles in inflammatory and joint destructive processes, these factors are also 
implicated in tumorigenesis. IL-6 plays a central part in the pathogenesis of several 
types of cancers [22]. To mention some, differential TLR-dependent IL-6 production is 
proposed to count for reduced liver cancer risk in females, due to an inhibitory effect of 
estrogen [252], and IL-6-induced cell proliferation and anti-apoptosis signaling plays a 
pivotal role in early colorectal cancer tumorigenesis [253-255]. It is of interest that 
cancer involving aberrant IL-6 signaling (e.g. colon, liver, lung) are linked to TLR 
activation and inflammation [252, 256-259]. Due to its angiogenetic effects, IL-8 is 
associated with increased tumorigenesis [260], and is, through activating its receptor 
CCXR7, reported to phosphorylate EGFR to induce the mitogenic cascade promoting 
prostate tumor growth [261]. Overexpression of MMPs characterize most malignant 
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tumors, and they are directly involved in tumor invasion and metastasis [262]. 
Moreover, we found cPLA2Į to modulate NF-țB activation. NF-țB is a crucial 
regulator of both carcinogenesis and inflammation, and provide a mechanistic link 
between these processes [263]. The observations of cPLA2Į-dependent regulation of 
these factors may thus contribute to enlighten potential mechanisms through which 
cPLA2Į can modulate tumorigenesis. 
In Papers II-IV, cPLA2Į involvement in TNF and TLR signaling pathways were 
in focus. While playing central roles in inflammation, both TNF and TLRs induce 
important signaling pathways and mediators implicated in tumorigenesis. The role of 
TNF in cancer development is janus-faced; its signaling can induce both positive and 
negative effects in cancer [264]. Despite its name generated from its initial discovery as 
being toxic to tumor cells, TNF also displays a potent tumor-promoting effect in mice 
[265]. TNF can promote cell survival, invasion, angiogenesis and tumor initiation [266, 
267], and is produced in excessive amounts by malignant cells in experimental and 
human cancers during tumor growth and spread [265, 266, 268, 269]. Furthermore, 
clinical trials suggest TNF blockade to be a useful therapeutic strategy in cancer 
treatment [270, 271].  
The traditional view of TLR signaling is the modulation of host defense and 
induction of inflammation in response to invading pathogens and tissue damage. 
However, it has become evident that the effects of TLR activation extend past inducing 
inflammation to include processes such as proliferation, survival and migration. TLR 
signaling may thus link inflammation to tissue repair, wound healing and cancer 
development [272]. TLR ligands augment proliferation, angiogenesis and metastasis 
and decrease apoptosis in various tumor types through NF-țB activation [273-275]. 
Moreover, several TLR polymorphisms are associated with cancer in a variety of tissues 
[272]. Thus, the modulating role of cPLA2Į in TNF- and TLR-induced signaling 
reported in Papers II-IV may also be of relevance in inflammation-induced 
tumorigenesis. This hypothesis needs further investigation in appropriate model 
systems, and is an exciting direction for future studies. 
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Even though our understanding of the inflammatory processes and links between 
inflammation, proliferation and cancer development is substantial and rapidly 
increasing, many mysteries remain. Inflammation in the context of cancer is not always 
“bad”. As always, the outcome of inflammation depend on balance; the cytokine in 
cancer can also contribute to driving the pathological process in a favorable direction 
[264]. At the beginning of the 20th century, the New York surgeon William Coley 
performed controversial research infecting cancer patients with “Coley’s mixed toxins”, 
an inflammatory-inducing bacterial extract (reviewed in [264]). Strikingly (if the 
published case histories are to be believed), he achieved impressive results. Today, we 
understand that “Coley’s mixed toxins” were powerful activators of TLRs [35], and that 
the tumor-reducing effects were achieved by triggering a beneficial  inflammatory 
response stimulating the immune system to target the tumor [264]. Several studies point 
to an anti-tumor effects of TLR signaling [272], and it is proposed that TLR-activation 
can induce a “re-education” of immune cells towards a tumor-suppressive phenotype 
through MyD88/NF-țȕ dependent pathways [276]. The mechanisms by which 
inflammation can be shifted towards a beneficial path during cancer therapy are not 
clear, but the idea is intriguing and encourage for more research in the field. This yet 
again underscores the need to understand underlying signaling mechanisms, and the 
delicate balance between the many and pleiotropic mediators of inflammation. 
 
4.4. cPLA2Į inhibition as a therapeutic strategy  
The development of TNF-blocking agents introduced a new era in RA treatment. 
However, the adverse effects including opportunistic infection, risk of recurrence and 
not to mention the significant number of non-responsive patients enlighten the need for 
new therapeutic targets; and cPLA2Į is emerging as a potential candidate. In murine 
models, cPLA2Į inhibition appears to be a promising therapeutic strategy in treating 
inflammatory arthritis [193, 194]. However, little is known about the detailed roles of 
cPLA2Į and thus consequences of cPLA2Į inhibition in the human body. However, 
thus far, increasing evidence from human cell culture studies, supplemented by the 
work presented in this thesis, suggest a central role for cPLA2Į in modulating important 
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signaling comprising inflammatory, joint destructive and possibly proliferative 
processes also in human cells.  
NSAIDs and COX2-specific inhibitors are effective in symptomatic relief in RA, 
however without affecting disease progression. COX2 inhibitors were developed to 
avoid the gastrointestinal adverse effects associated with long-term NSAID use. 
However, COX2-specific inhibitors turned out to display an increased incidence of 
myocardinal infarction and stroke [277], possibly due to a skewed TBX2/PGI2 ratio 
[278]. Both TBX2 and PGI2 are metabolized from AA downstream cPLA2Į action, and 
PLA2 inhibition is as might be expected shown to decrease TBX2 biosynthesis [279]. In 
a patient with genetic mutations in the PLA2G4A gene [280], the TBX2/PGI2 ratio 
seemed to be skewed in a beneficial direction compared to healthy control patients 
[280], thus possibly indicating a favourable effect of targeting cPLA2Į compared to 
selective COX2 inhibition. This hypothesis however, is not yet experimentally tested. 
Another example emphasizing the complexity in COX2-mediated lipid signaling is 
described by Gilroy et al. In a pleurisy rat model, they found an early peak in COX2 
protein associated with maximal PGE2 synthesis during the onset of inflammation. 
However, at a later time-point, another, more powerful peak in COX2 protein was 
detected, coinciding with resolution of inflammation, decreased PGE2 synthesis and 
increased levels of the anti-inflammatory PGD2 and PGJ2. Inhibition of COX enzymes 
reversed this response, inhibiting early inflammation, but exacerbating inflammation at 
a later time point, possibly through inhibition of PGD2 and PGJ2 synthesis thus acting 
to inhibit resolution of inflammation. It is furthermore documented that different 
prostaglandins derived downstream COX2 activity can affect NF-țB in opposite ways; 
PGE2 and its analogs activate, while PGJ2 inhibits NF-țB activation. Thus, the balance 
between the different lipid metabolites is of vital importance [281]. It remains to be 
elucidated how cPLA2Į inhibition affects the composition of lipid mediators in general, 
and whether cPLA2Į inhibition provides a more balanced effect on COX-derived 
prostanoids. These are important questions to address in future studies. 
Several pathways are proposed as potential future targets in RA therapy 
including MAPK signaling [282] and NF-țB activation [215]. However, these pathways 
orchestrate important processes in addition to pathologic inflammation, thus the 
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challenge lies in directly targeting pathological inflammation, permitting beneficial 
signaling necessary for a “healthy” immune response and homeostasis [215, 282]. Anti-
TNF therapies are also, as previously mentioned, linked to adverse effects associated 
with a global suppression of the immune response [25]. The above-mentioned cPLA2Į 
deficient patient [280] displayed platelet dysfunction and multiple recurrent small 
ulcers, implying the potential harmful consequences of a too drastic reduction in 
cPLA2Į activity, which needs to be considered when considering safety and 
effectiveness of therapeutic cPLA2Į inhibition. A general observation from the results 
presented in Papers II-IV is the normalizing effect of cPLA2Į inhibition in response to 
pro-inflammatory stimuli; AA release and PGE2 levels were not short-circuited, but 
reduced to unstimulated control levels thereby possibly permitting basal house-hold 
activities. The same tendency was observed concerning gene transcription and protein 
production as cPLA2Į inhibition served to reduce, not obliterate the expressions. Our 
results rather indicate a dampening effect of cPLA2Į inhibition in multiple pro-
inflammatory signaling pathways acting to normalize downstream cellular 
consequences. This may represent a favourable feature of cPLA2Į as a therapeutic 
target as the inflammatory response depends on a delicate balance between many and 
often highly pleiotropic mediators. A slight shift in their composition may contribute to 
direct the inflammatory response in favor of resolution and repair. However, it remains 
to see if this hypothesis applies in animals or eventually in the human body, an exciting 
question for future research.  
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5. Conclusions  
The overall objective of this work was to investigate the role of cPLA2Į and lipid 
messengers in molecular mechanisms involved in chronic inflammation. Our results 
were also interpreted in light of evaluating cPLA2Į as a future therapeutic target in 
inflammatory disease, RA in particular. In Paper I, we found PAF to be a regulator of 
keratinocyte proliferation, migration and eventually re-epithelialization, thus promoting 
wound healing rather than inflammation. In Paper II, we found cPLA2Į to act as a 
regulator of synoviocyte TNF-induced signaling modulating the production of pro-
inflammatory and joint destructive effectors. In Paper III, the regulatory role of 
cPLA2Į was found to comprise TLR2-induced signaling. This signaling was elucidated 
in more detail in Paper IV, where cPLA2Į, activated by MAPKs p38 and ERK1/2, was 
found to regulate TLR2-induced NF-țB activation and subsequent IL-6 generation, 
possibly through COX/PGE2-dependent pathways. 
Taken together, our findings demonstrate the central role of cPLA2Į, possibly 
via regulating PGE2 levels, and PAF in modulating important signaling cascades 
promoting inflammation and proliferation. Our results support a future role for cPLA2Į 
as therapeutic target in treating rheumatoid arthritis and other chronic inflammatory 
conditions. Moreover, the role of cPLA2Į in regulating (hyper)proliferation and 
possibly tumorigenesis is exciting for future studies.  
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Paper II

&\WRVROLF3KRVSKROLSDVH$5HJXODWHV71),QGXFHG
3URGXFWLRQRI-RLQW'HVWUXFWLYH(IIHFWRUVLQ6\QRYLRF\WHV
5DQGL06RPPHUIHOWู$VWULG-)HXHUKHUPู.\PU\-RQHV͞%HULW-RKDQVHQ
'HSDUWPHQWRI%LRORJ\1RUZHJLDQ8QLYHUVLW\RI6FLHQFHDQG7HFKQRORJ\7URQGKHLP1RUZD\
$EVWUDFW
,QWURGXFWLRQ5KHXPDWRLGDUWKULWLV 5$ LV DQ LQIODPPDWRU\GLVHDVHRI WKH MRLQW FKDUDFWHUL]HGE\ FKURQLF V\QRYLWLV
FDXVLQJ SDLQ VZHOOLQJ DQG ORVV RI IXQFWLRQ GXH WR GHVWUXFWLRQ RI FDUWLODJH DQG ERQH 7KH FRPSOH[ VHULHV RI
SDWKRORJLFDOHYHQWVRFFXUULQJLQ5$LVODUJHO\UHJXODWHGYLDH[FHVVLYHSURGXFWLRQRISURLQIODPPDWRU\F\WRNLQHVWKH
PRVWSURPLQHQWEHLQJWXPRUQHFURVLVIDFWRU71)7KHREMHFWLYHRIWKLVZRUNZDVWRHOXFLGDWHSRVVLEOHLQYROYHPHQW
RI JURXS ,9$ F\WRVROLF SKRVSKROLSDVH $ F3/$Į LQ 71)LQGXFHG UHJXODWLRQ RI V\QRYLWLV DQG MRLQW GHVWUXFWLYH
HIIHFWRUVLQ5$WRHYDOXDWHWKHSRWHQWLDORIF3/$ĮDVDIXWXUHWKHUDSHXWLFWDUJHW
0HWKRGV 7KH LQYROYHPHQW RI F3/$Į LQ WXPRU QHFURVLV IDFWRU 71)LQGXFHG LQWUDFHOOXODU VLJQDOLQJ FDVFDGHV LQ
V\QRYLRF\WHV V\QRYLDO ILEUREODVWOLNH FHOOV ZDV DQDO\]HG E\ DUDFKLGRQLF DFLG $$ UHOHDVH DVVD\ V\QRYLRF\WH
HQ]\PH DFWLYLW\ DVVD\ JHQH H[SUHVVLRQ DQDO\VLV E\ UHDOWLPH3&5 DQG(/,6$ LPPXQRDVVD\ IRU WKH GHWHFWLRQ RI
SURVWDJODQGLQ(3*(LQWHUOHXNLQ,/DQGVWURPHO\VLQ003UHVSHFWLYHO\
5HVXOWV,QKLELWRUVRIF3/$ĮHQ]\PHDFWLYLW\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VLJQLILFDQWO\UHGXFHG71)LQGXFHGFHOOXODUUHOHDVHRI
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,QWHUHVWLQJO\ F3/$Į LQKLELWLRQ DIIHFWHG VHYHUDO NH\ SRLQWV RI WKH DUDFKLGRQ\O FDVFDGH $$UHOHDVH
F\FORR[\JHQDVH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H[SUHVVLRQDQG3*(SURGXFWLRQ)XUWKHUPRUHWKHUHVXOWVVXJJHVWWKDWF3/$ĮLVVXEMHFW
WR WUDQVFULSWLRQDO DXWRUHJXODWLRQ DV LQKLELWLRQ RI F3/$Į UHVXOWHG LQ UHGXFHG 3/$*$ JHQH H[SUHVVLRQ LQ 71)
VWLPXODWHGV\QRYLRF\WHV
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F3/$ĮDSSHDUVWREHDQLPSRUWDQWUHJXODWRURIFHQWUDOHIIHFWRUVRILQIODPPDWLRQDQGMRLQWGHVWUXFWLRQ
QDPHO\003 ,/&2;DQG3*('HFUHDVHG WUDQVFULSWLRQRI WKH3/$*$DQG&2;JHQHV LQ UHVSRQVH WR
F3/$Į HQ]\PH LQKLELWLRQ IXUWKHU VXJJHVW D VHOIUHLQIRUFLQJ HIIHFW RI F3/$Į LQKLELWLRQ LQ UHVSRQVH WR 71)
&ROOHFWLYHO\WKHVHUHVXOWVVXSSRUWWKDWF3/$ĮLVDQDWWUDFWLYHWKHUDSHXWLFWDUJHWFDQGLGDWHDVLWVLQKLELWLRQUHGXFHV
WKHSURGXFWLRQRIPXOWLSOHNH\SURLQIODPPDWRU\IDFWRUVLQYROYHGLQ5$SDWKRJHQHVLV
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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3XEOLVKHG'HFHPEHU
7KLVLVDQRSHQDFFHVVDUWLFOHIUHHRIDOOFRS\ULJKWDQGPD\EHIUHHO\UHSURGXFHGGLVWULEXWHGWUDQVPLWWHGPRGLILHGEXLOWXSRQRURWKHUZLVHXVHGE\
DQ\RQHIRUDQ\ODZIXOSXUSRVH7KHZRUNLVPDGHDYDLODEOHXQGHUWKH&UHDWLYH&RPPRQV&&SXEOLFGRPDLQGHGLFDWLRQ
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,QWURGXFWLRQ
5KHXPDWRLG DUWKULWLV 5$ LV DQ DXWRLPPXQH DQG V\VWHPLF
LQIODPPDWRU\ GLVHDVH DIIHFWLQJ  RI WKH SRSXODWLRQ
ZRUOGZLGH ,Q5$ FKURQLF V\QRYLWLV FDXVHVSDLQ VZHOOLQJDQG
ORVVRI MRLQW IXQFWLRQGXH WRGHJUDGDWLRQRIFDUWLODJHDQGERQH
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)/6 LQ WKH
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DQG DGKHVLRQ PROHFXOHV WKXV SHUSHWXDWLQJ LQIODPPDWLRQ DQG
MRLQW GHVWUXFWLRQ >@ $ NH\ PHFKDQLVP LQ WKH GHVWUXFWLYH
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LQIODPPDWRU\F\WRNLQHWXPRUQHFURVLVIDFWRU71)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RYHUH[SUHVVHG LQ 5$ V\QRYLXP ZKHUH LW HOLFLWV D YDULHW\ RI
ELRORJLFDO HIIHFWV RQ LQIODPPDWLRQ DQG LPPXQLW\ LQFOXGLQJ
PRGXODWLRQ RI JHQH H[SUHVVLRQ DQG LQIODPPDWRU\ MRLQW
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HVWHU ERQG RI PHPEUDQH JO\FHURSKRVSKROLSLGV 7KH
DUDFKLGRQ\O VSHFLILF JURXS ,9$ F\WRVROLF 3/$ HQ]\PH
F3/$Į HQFRGHG E\ WKH 3/$*$ JHQH LV D PDMRU
FRQWULEXWRU WR WKH HOHYDWHG OHYHOV RI $$ LQ LQIODPPDWLRQ >@
F3/$Į DFWLYLW\ LV UHJXODWHG DW PDQ\ OHYHOV E\ LQFUHDVHG
LQWUDFHOOXODU&DOHYHOVLQUHVSRQVHWRSURLQIODPPDWRU\VWLPXOL
E\ ELQGLQJ WR OLSLG VHFRQG PHVVHQJHUV E\ SKRVSKRU\ODWLRQ
LQGXFHGE\NLQDVHVDQGE\GHQRYRJHQHWUDQVFULSWLRQ>±@
)ROORZLQJF3/$ĮDFWLYDWLRQWKHUHOHDVHG$$LVHQ]\PDWLFDOO\
PHWDEROL]HG WRELRDFWLYHHLFRVDQRLGV LQFOXGLQJSURVWDJODQGLQV
WKURPER[DQHVOLSR[LQVDQGOHXNRWULHQHV>@3URVWDJODQGLQ(
3*( LV V\QWKHVL]HG IURP $$ WKURXJK WKH F\FORR[\JHQDVH
&2; SDWKZD\ DQG LV JHQHUDOO\ UHFRJQL]HG DV D SRWHQW OLSLG
UHJXODWRU RI DFWLYH LQIODPPDWLRQ >@ 7KH EHQHILFLDO DQWL
LQIODPPDWRU\ HIIHFW RI UHGXFLQJ 3*( V\QWKHVLV LV ZHOO
UHFRJQL]HGDQGDVVXFKQRQVWHURLGDODQWLLQIODPPDWRU\GUXJV
16$,'6 WDUJHWLQJ WKH &2; HQ]\PHV DUH ZLGHO\ XVHG IRU
V\PSWRPDWLF UHOLHI LQ 5$ >@ +RZHYHU ORQJ WHUP XVH RI
16$,'6KDVDGYHUVHHIIHFWVHJDIIHFWLQJWKHJDVWURLQWHVWLQDO
DQGFDUGLRYDVFXODUV\VWHPDQGERQHKRPHRVWDVLV>±@7KH
GHYHORSPHQW RI 71)EORFNLQJ DJHQWV KDV UHYROXWLRQL]HG WKH
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QRWUHVSRQGVXFFHVVIXOO\ WRWUHDWPHQW>@$QWL71)WKHUDSLHV
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7KHUHIRUH D VHDUFK IRU DOWHUQDWLYH WKHUDSHXWLF WDUJHWV LV RI
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6HYHUDO OLQHV RI HYLGHQFH SRLQW WR D UROH IRU F3/$Į LQ
DUWKULWLV DQG LQIODPPDWLRQ DOWKRXJK WKH H[DFWPHFKDQLVPV RI
KRZ F3/$Į UHJXODWHV GLVHDVH DFWLYLW\ LV QRW IXOO\ HOXFLGDWHG
>±@ 7KH DLP RI WKLV VWXG\ ZDV WR LQYHVWLJDWH WKH
LQYROYHPHQWRIF3/$Į LQ MRLQWDQGERQHGHVWUXFWLYHVLJQDOLQJ
LQKXPDQV\QRYLRF\WHV:HLGHQWLILHGF3/$ĮDVDUHJXODWRURI
71)LQGXFHG H[SUHVVLRQ RI NH\ SOD\HUV LQ 5$ SDWKRORJ\
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QHXWURSKLO UHFUXLWPHQW QDPHO\ VWURPHO\VLQ 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UHGXFHG H[SUHVVLRQ RI 3/$*$P51$ LQ UHVSRQVH WR 71)
+HQFH RXU UHVXOWV VXSSRUW WKH FRPSUHKHQVLRQ WKDW F3/$Į
PD\EHDPDMRUFRQWULEXWRUWRV\QRYLWLVDQGMRLQWGHVWUXFWLRQLQ
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0DWHULDOVDQG0HWKRGV
5HDJHQWV
5HFRPELQDQW KXPDQ 71) ZDV IURP 5	' V\VWHPV
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 ZDV IURP (Q]R /LIH 6FLHQFHV )DUPLQJGDOH 1< 86$
3%6 ZDV IURP 2[RLG 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>+@$$ DQG OLTXLG VFLQWLOODWLRQ FRFNWDLO
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0286$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 LQ
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GHVFULEHG >±@ %URPRHQRO ODFWRQH  ȝ0 DQG
GLWKLRWKUHLWROP0ZHUHLQFOXGHGLQDOOUHDFWLRQVWRLQKLELW
DFWLYLW\RIL3/$DQGV3/$>@
5HDOWLPHUHYHUVHWUDQVFULSWLRQSRO\PHUDVHFKDLQ
UHDFWLRQ573&5
7RWDO 51$ ZDV LVRODWHG XVLQJ 51HDV\ PLQLNLW 4LDJHQ
DFFRUGLQJWRNLWSURWRFRO51$FRQFHQWUDWLRQVDQGLQWHJULW\ZDV
PRQLWRUHG E\ 1DQR'URS VSHFWURSKRWRPHWULF PHDVXUHPHQW
1DQR'URS 7HFKQRORJLHV ,QF:LOPLQJWRQ'( 86$ DQG WRWDO
51$  J ZDV UHYHUVH WUDQVFULEHG DV GHVFULEHG LQ >@
6SHFLILFSULPHUVIRU,/003&2;3/$*$DQG*$3'+
ZLWK WKH IROORZLQJVHQVHDQGDQWLVHQVHSULPHUVZHUHXVHG LQ
VWDQGDUG UHDOWLPH 573&5V ZLWK 6<%5 *UHHQ DV
IOXRUHVFHQFH UHSRUWHU ,/ 
*$&$7$&7&&$$$&&777&&$& DQG 
&77&7&&$&$$&&&7&7*& 003 
7*$7*$$&$$7**$&$$$**$7$&  DQG 
&7*7*$*7*$*7*$7$*$*7** &2; 
****$7&$***$7*$$&777  DQG 
7**&7$&$$$$*&7***$$*  3/$*$ 
&$7*&&&$*$&&7$&*$777  DQG 
&&&$$7$7**&7$&&$&$**  *$3'+ 
&\WRVROLF3/$LQ5KHXPDWRLG$UWKULWLV
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&$7&$$*$$**7**7*$$*&$* DQG 
7*7$*&&$$$77&*77*7&$7$&& &T YDOXHV IRU HDFK
DPSOLILFDWLRQ FXUYHZHUH FDOFXODWHG E\ WKH0[3 VRIWZDUH
6WUDWDJHQH)ROGFKDQJHVLQP51$H[SUHVVLRQDQGVWDWLVWLFDO
DQDO\VLVZHUHFDOFXODWHGE\WKH5(67VRIWZDUH>@ZLWK
PHDQ3&5UHDFWLRQHIILFLHQFLHVFDOFXODWHGE\ WKH/LQ5HJ3&5
VRIWZDUH>@XVLQJ*$3'+DVUHIHUHQFHJHQH
(Q]\PHOLQNHGLPPXQRVRUEHQWDVVD\(/,6$
(/,6$ DQDO\VHV ZHUH SHUIRUPHG DFFRUGLQJ WR WKHLU
UHVSHFWLYH NLW SURWRFROV 7KH UHDGRXW IRU DOO (/,6$V ZDV
FDUULHGRXWZLWKD0XOWLVFDQSODWHUHDGHU$VFHQW/DEV\VWHPV
7KH FRUUHVSRQGLQJ $VFHQW VRIWZDUH IRU 0XOWLVFDQ 9HUVLRQ
ZDVXVHGWRREWDLQWKHGDWD0HDQHVWLPDWHG,&YDOXH
IRU 3*( SURGXFWLRQ ZDV FDOFXODWHG IURP  LQGHSHQGHQW
H[SHULPHQWV
6WDWLVWLFDODQDO\VLV
)RU$$UHOHDVHDQG(/,6$DQDO\VLVVWDWLVWLFDODQDO\VHVZHUH
SHUIRUPHG LQ 6366 6WDWLVWLFV  XVLQJ RQHZD\ $129$ DW
FRQILGHQFH OHYHO LQFRQMXQFWLRQZLWK7XNH\+6'WHVW)RU
UHDOWLPH3&5GDWD VWDWLVWLFDO DQDO\VLVZDV SHUIRUPHGE\ WKH
5(67  VRIWZDUH >@ 'LIIHUHQFHV ZHUH FRQVLGHUHG
VLJQLILFDQWDWS
5HVXOWV
71)LVDSRWHQWLQGXFHURIMRLQWGHVWUXFWLYHUHJXODWRUV
LQV\QRYLRF\WHV
003 ,/ DQG 3*( DUH LPSRUWDQW UHJXODWRUV RI
LQIODPPDWLRQ DQG MRLQW GHVWUXFWLRQ LQ 5$ >@ 0DWUL[
PHWDOORSURWHLQDVHV 003V DUH PDLQ FRQWULEXWRUV WR 5$
FDUWLODJHGHVWUXFWLRQDQGWKHOHYHOVRIVHYHUDO003VXEJURXSV
LQFOXGLQJ003DUHHOHYDWHGLQ5$V\QRYLDOIOXLG>@7KH
FKHPRNLQH ,/ LVRYHUH[SUHVVHG LQ5$V\QRYLXPDQGDFWVDV
DQ DQJLRJHQLF IDFWRU DQG FKHPRDWWUDFWDQW IRU QHXWURSKLOV
WKHUHE\PDLQWDLQLQJ SHUVLVWHQWPLJUDWLRQ RI LQIODPPDWRU\ FHOOV
LQWRWKHV\QRYLXP>@ZKLOH3*(LVDSRZHUIXOLQGXFHURI
LQIODPPDWLRQ >@ $V 71) LV NQRZQ WR LQGXFH ERWK ,/ DQG
003 >@ ZH ILUVW FKDUDFWHUL]HG EDVDO DQG 71)LQGXFHG
JHQH H[SUHVVLRQ E\ UHDOWLPH 3&5 DQG SURWHLQ E\ (/,6$ WR
MXVWLI\WKHXVHRI6:V\QRYLRF\WHVDVDPRGHOIRUVWXG\LQJ
WKH71) UHVSRQVH ,QGHHG 71) LQFUHDVHGP51$H[SUHVVLRQ
RI003DQG,/E\IROGSDQG
IROG S   UHVSHFWLYHO\ )LJXUH $ DQG %
&RUUHVSRQGLQJO\ 71)LQGXFHG SURWHLQ H[SUHVVLRQ ZDV
REVHUYHG DV LQGLFDWHG E\ D WZRIROG LQFUHDVH LQ 003 OHYHOV
IURPQJP/ WRQJP/ S DQGD
ILYHIROG LQFUHDVH LQ ,/ SURWHLQ IURP    QJP/ WR
QJP/S)LJXUH&
$V ZH DLPHG WR LQYHVWLJDWH LQYROYHPHQW RI F3/$Į LQ
UHJXODWLQJ 71)LQGXFHG H[SUHVVLRQ RI WKHVH PHWDEROLWHV ZH
IXUWKHU FKDUDFWHUL]HG WKH 3/$*$ JHQH H[SUHVVLRQ LQ
V\QRYLRF\WHV :H IRXQG WKH 3/$*$ WUDQVFULSW WR EH
H[SUHVVHGLQXQWUHDWHGFHOOVDQGIXUWKHULQGXFHGIROG
E\ 71) S   )LJXUH ' &ROOHFWLYHO\ WKH 6:
V\QRYLRF\WHPRGHOV\VWHPZDVIRXQGVXLWDEOHIRU LQYHVWLJDWLQJ
SRWHQWLDO LQYROYHPHQW RI F3/$Į LQ UHJXODWLQJ 71)LQGXFHG
VLJQDOLQJUHODWHGWRMRLQWGHVWUXFWLYHSURFHVVHVRFFXUULQJLQWKH
5$V\QRYLXP
$9;(IILFLHQWO\5HGXFH$$5HOHDVHDQG3*(
3URGXFWLRQ
7KH$$PHWDEROLWH3*(LVUHFRJQL]HGDVDSRWHQWUHJXODWRU
RILQIODPPDWLRQDQGWKHEHQHILWVRIUHGXFLQJSDWKRORJLFDO3*(
OHYHOV DUH FRPPRQO\ DFFHSWHG >@:H DLPHG WR LQYHVWLJDWH
WKH HIIHFW RI WKH UHFHQWO\ GHVFULEHG F3/$Į LQKLELWRU $9;
>@ RQ FHOOXODU $$ UHOHDVH DQG WRWDO 3*( V\QWKHVLV LQ WKH
V\QRYLRF\WH PRGHO V\VWHP $9; GRVHGHSHQGHQWO\
LQKLELWHG WKH 71)LQGXFHG$$ UHOHDVHZLWK DPHDQ HVWLPDWHG
,&YDOXHRIȝ0)LJXUH$7KLVHVWLPDWHLVEDVHG
RQ  LQGHSHQGHQW H[SHULPHQWV $9; DORQH PRGHVWO\
UHGXFHGEDVDO$$UHOHDVHLQDGRVHGHSHQGHQWPDQQHU0
$9; UHGXFHGEDVDO$$ UHOHDVHE\0DQG
0E\DQG0E\)XUWKHUPRUH$9;ZDV
IRXQG WR GLVSOD\ ORQJODVWLQJ LQKLELWRU\ HIIHFWV HYLGHQFHG E\
UHGXFHG 71)LQGXFHG $$ UHOHDVH WR    RI EDVDO OHYHO
IROORZLQJ  KUV RI 71) VWLPXODWLRQ S   )LJXUH %
$9; LQKLELWRU\ HIILFDF\ ZDV FRPSDUHG WR WKH ZLGHO\ XVHG
FRPPHUFLDO F3/$Į LQKLELWRU $7. >@ $7. UHGXFHG 71)
LQGXFHG$$UHOHDVHLQDVLPLODUIDVKLRQDV$9;)LJXUH$
KRZHYHUZLWKVLJQLILFDQWO\ ORZHUHIILFDF\ S DV LQGLFDWHG
E\WKHKLJKHUPHDQHVWLPDWHG,&YDOXHRIȝ0
+DYLQJVKRZQWKDWWKHLQGXFLQJHIIHFWVRI71)RQ$$UHOHDVH
DUH QRUPDOL]HG WRZDUG EDVDO OHYHO E\ F3/$Į LQKLELWRUV ZH
QH[WDLPHGWRLQYHVWLJDWHLIWKLVILQGLQJZDVDOVRUHIOHFWHGLQWKH
OHYHORI3*(SURGXFWLRQ%\(/,6$DQDO\VLVZHGHPRQVWUDWHG
WKDWSURGXFWLRQRI3*(LQFUHDVHGILYHIROGLQUHVSRQVHWR71)
VWLPXODWLRQFRPSDUHG WREDVDO OHYHO IURPQJP/WR
QJP/S)LJXUH&71)LQGXFHG3*(
SURGXFWLRQZDV GRVHGHSHQGHQWO\ UHGXFHG E\$9;ZLWK D
PHDQHVWLPDWHG,&YDOXHRIȝ07KH,&HVWLPDWH
LV EDVHG RQ WKUHH LQGHSHQGHQW H[SHULPHQWV $9; DORQH
DOVR VLJQLILFDQWO\ GHFUHDVHG 3*( SURGXFWLRQ LQ XQVWLPXODWHG
FHOOVLQDGRVHGHSHQGHQWPDQQHUE\LQȝ0LQ
 ȝ0 DQG  LQ  ȝ0 FRQFHQWUDWLRQV FRPSDUHG WR
XQWUHDWHGFRQWUROVDPSOHV
6LQFH WKH PHWDEROL]DWLRQ RI $$ LQWR 3*( LQ UHVSRQVH WR
71) LPSOLHV WKH LQYROYHPHQW RI WKH &2; SDWKZD\ LW ZDV RI
LQWHUHVW WR LQYHVWLJDWH WKH H[SUHVVLRQ RI WKH LQGXFLEOH &2;
HQ]\PH :H VKRZ WKDW LQ UHVSRQVH WR 71) &2; P51$
H[SUHVVLRQLQFUHDVHGIROGSDQLQGXFWLRQWKDW
ZDVVLJQLILFDQWO\ UHGXFHGE\IROORZLQJ$9; WUHDWPHQW
S   )LJXUH ' 1H[W ZH LQYHVWLJDWHG SRWHQWLDO
WUDQVFULSWLRQDO UHJXODWLRQ RI WKH F3/$Į JHQH 3/$*$:H
IRXQG WKDW WKH ILYHIROG LQGXFWLRQ E\ 71) ZDV VLJQLILFDQWO\
UHGXFHGE\S)LJXUH'VXJJHVWLQJWKDWF3/$Į
DFWLYLW\PD\EHVXEMHFW WRDXWRUHJXODWLRQ LQ UHVSRQVH WR71)
VWLPXODWLRQ$9;WUHDWPHQWDORQHGLGQRWVLJQLILFDQWO\DIIHFW
EDVDO WUDQVFULSWLRQ RI HLWKHU JHQH UHVXOWV QRW VKRZQ+HQFH
$9;VHUYHGWRQRUPDOL]HQRWVKRUWFLUFXLWJHQHH[SUHVVLRQ
WKHUHE\ VWLOO DOORZLQJ EDVDO KRXVHKROG DFWLYLWLHV 7DNHQ
WRJHWKHUWKHLQKLELWRU\HIIHFWRI$9;ZDVHYLGHQWDWVHYHUDO
UHJXODWRU\ OHYHOV DQG DW GLIIHUHQW SRLQWV LQ WLPH F3/$Į DQG
&2;HQ]\PHDFWLYLWLHVDUHQRUPDOL]HG WRZDUGVEDVDODFWLYLW\
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OHYHOV DV PRQLWRUHG E\ PHDQV RI $$ UHOHDVH DQG 3*(
SURGXFWLRQ DQG VHFUHWLRQ ,Q SDUDOOHO &2; DQG 3/$*$
JHQH H[SUHVVLRQ DUH DOVR UHGXFHG WRZDUGV EXW QRW EHORZ
EDVDO OHYHOV 7KLV VXJJHVWV WKDW WKH F3/$Į HQ]\PH KDV DQ
LPSRUWDQWUHJXODWRU\UROHDWVHYHUDOSRLQWVLQWKH$$FDVFDGHLQ
V\QRYLRF\WHV
$9;LQKLELWVF3/$ĮDFWLYLW\LQFHOOO\VDWHV
7RYDOLGDWHWKHLQKLELWRU\HIIHFWRI$9;RQF3/$ĮLQRXU
PRGHO V\VWHP ZH LQYHVWLJDWHG WKH SRWHQF\ RI $9; WR
UHVWUDLQF3/$ĮHQ]\PHDFWLYLW\ LQFHOO O\VDWHV IURPXQWUHDWHG
DQG 71)VWLPXODWHG FHOOV /\VDWHV RI 71)VWLPXODWHG FHOOV
GLVSOD\HGDQ LQFUHDVH LQDFWLYLW\RIF3/$ĮFRPSDUHG WR
XQWUHDWHG FHOOV DV LQGLFDWHG E\ LQFUHDVHG K\GURO\VLV DQG
UHOHDVH RI &$$ IURP SKRVSDWLG\OFKROLQH YLVXDOL]HG E\ 7/&
FKURPDWRJUDSK\ )LJXUH ' 7KLV VWLPXODWRU\ HIIHFW LV
FRQVLVWHQW ZLWK WKH GHWHFWHG LQGXFWLRQ RI $$ UHOHDVH E\ 71)
GHVFULEHG DERYH DQG YDOLGDWHV WKH DFWLYDWLRQ RI F3/$Į LQ
6:FHOOVLQUHVSRQVHWR71)'HWHFWLRQRIF3/$ĮDFWLYLW\
LQ O\VDWHV IURP XQVWLPXODWHG FHOOV LQGLFDWH D EDVDO HQ]\PH
DFWLYLW\ LQ V\QRYLRF\WHV DV SUHYLRXVO\ GHVFULEHG LQ SULPDU\
UKHXPDWRLG V\QRYLRF\WHV >@ DQG FRUUHODWHV WR WKH EDVDO
UHOHDVH RI $$ GHWHFWHG LQ XQVWLPXODWHG FHOOV )LJXUH $
)XUWKHUPRUH$9;HIILFLHQWO\ LQKLELWHGDFWLYLW\RIF3/$ĮLQ
O\VDWHVIURPXQVWLPXODWHGFHOOVDVZHOODV71)VWLPXODWHGFHOOV
)LJXUH ' 7KH FDSDFLW\ RI $9; LQ LQKLELWLQJ F3/$Į
HQ]\PH DFWLYLW\ LQ FHOO O\VDWHV DJUHHV ZLWK WKH SUHYLRXVO\
UHSRUWHG HIIHFW RQ UHFRPELQDQW F3/$Į >@ 7RJHWKHU WKHVH
UHVXOWV VXSSRUW RXU LQWHUSUHWDWLRQ WKDW F3/$Į LV DFWLYDWHG E\
71)LQV\QRYLRF\WHVDQGWKDW$9;GLUHFWO\LQKLELWVF3/$Į
DFWLYLW\UHVXOWLQJLQUHGXFHGGRZQVWUHDP$$UHOHDVHDQG3*(
SURGXFWLRQ
003H[SUHVVLRQLVUHJXODWHGE\$9;
7R HYDOXDWH D SRWHQWLDO UROH IRU F3/$Į LQ UHJXODWLQJ
GHVWUXFWLRQ RI FDUWLODJH LQ 5$ ZH DQDO\]HG WKH HIIHFWV RI
$9; RQ 003 H[SUHVVLRQ ,QGHHG $9; GRVH
GHSHQGHQWO\ UHGXFHG 71)LQGXFHG003 WUDQVFULSWLRQZLWK D
)LJXUH   ,QKLELWLRQ RI F3/$Į UHGXFHV 71)LQGXFHG H[SUHVVLRQ RI 3/$*$ &2; 003 DQG ,/  )LEUREODVWOLNH
V\QRYLRF\WHVZHUHWUHDWHGZLWK$9;KUVLQLQGLFDWHGFRQFHQWUDWLRQV$%0&RU0'SULRUWR71)VWLPXODWLRQ
QJP/KUV7RWDO51$ZDVLVRODWHGDQGWUDQVFULSWLRQRI003$DQG,/%3/$*$DQG&2;'ZDVDQDO\]HGE\
UHDOWLPH3&5DVGHVFULEHGLQWKH0HWKRGVVHFWLRQ$PSOLILFDWLRQHIILFLHQF\RIDOOSULPHUSDLUVZHUHFDOFXODWHGE\WKH/LQ5HJ3&5
VRIWZDUH DQG IROGFKDQJH LQ JHQH H[SUHVVLRQ FRPSDUHG WR XQWUHDWHG VDPSOHVZDV FDOFXODWHG E\ WKH5(67  VRIWZDUHZLWK
*$3'+DVUHIHUHQFHJHQH6XSHUQDWDQWVZHUHFROOHFWHGDQGDQDO\]HGE\(/,6$IRU003DQG,/SURWHLQ&DVGHVFULEHGLQWKH
0HWKRGVHFWLRQQRWHVWDUWLQJSRLQWRI<D[LVDW'DWDVKRZQLQDOOJUDSKVDUHPHDQ6(0$%'RUPHDQ6'&IROG
FKDQJHFRPSDUHGWRXQWUHDWHGVDPSOHVIRURQHUHSUHVHQWDWLYHRIDWOHDVWWKUHHLQGHSHQGHQWH[SHULPHQWVSHUIRUPHGLQGXSOLFDWHV
6LJQLILFDQFHLVLQGLFDWHGDVIROORZV$SYVFRQWUROSSYVFRQWURODQG71)WUHDWHGFHOOV%SYVFRQWUROS
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PD[LPXPLQKLELWLRQRIDWȝ0S)LJXUH$%DVDO
003 P51$ H[SUHVVLRQ ZDV QRW VLJQLILFDQWO\ DIIHFWHG E\
$9;DORQHUHVXOWVQRWVKRZQ0RUHRYHUWKH71)LQGXFHG
WZRIROG LQFUHDVH LQ 003 SURWHLQ VHFUHWLRQ ZDV VLJQLILFDQWO\
UHGXFHGE\$9;E\ IURPQJP/ WR 
QJP/S)LJXUH&7KHVHUHVXOWVVXJJHVWDUROH
RI F3/$Į LQ UHJXODWLQJ 71)LQGXFHG 003 H[SUHVVLRQ LQ
KXPDQV\QRYLRF\WHV
,/H[SUHVVLRQLVUHJXODWHGE\$9;
1H[W WKH HIIHFW RI $9; LQ UHJXODWLQJ H[SUHVVLRQ RI WKH
NQRZQQHXWURSKLODWWUDFWDQW,/ZDVLQYHVWLJDWHGE\43&5DQG
(/,6$ LPPXQRDVVD\ $9; GRVHGHSHQGHQWO\ UHGXFHG
71)LQGXFHG XSUHJXODWLRQ RI ,/ WUDQVFULSWLRQ ZLWK D
PD[LPXPLQKLELWLRQRIDWȝ0S)LJXUH%%DVDO
,/ JHQH H[SUHVVLRQ ZDV QRW DIIHFWHG E\ $9; DORQH
UHVXOWV QRW VKRZQ $9; DOVR UHGXFHG 71)LQGXFHG ,/
SURWHLQVHFUHWLRQVLJQLILFDQWO\E\IURPQJP/
WRQJP/S)LJXUH&$FFRUGLQJO\RXU
UHVXOWV VXJJHVW WKDW LQ KXPDQ V\QRYLRF\WHV 71)LQGXFHG ,/
H[SUHVVLRQPD\EHUHJXODWHGE\F3/$Į
'LVFXVVLRQ
,Q5$FKURQLFLQIODPPDWLRQDQGMRLQWGHVWUXFWLRQLVGULYHQE\
H[FHVVLYH SURGXFWLRQ RI SURLQIODPPDWRU\ F\WRNLQHV
FKHPRNLQHV DQG HLFRVDQRLGV ,Q WKLV VWXG\ E\ DSSO\LQJ WKH
FKHPLFDOF3/$ĮLQKLELWRUV$9;DQG$7.ZHGHPRQVWUDWH
WKDW F3/$Į PD\ EH DQ LPSRUWDQW HIIHFWRU RI 71) LQ
LQWUDFHOOXODU VLJQDOLQJ GLUHFWO\ UHODWHG WR V\QRYLWLV )LJXUH 
VXPPDUL]HV WKH K\SRWKHVL]HG LQYROYHPHQW RI F3/$Į LQ
)LJXUH  F3/$Į UHJXODWHV 71)LQGXFHG$$ UHOHDVH DQG3*( V\QWKHVLV  6: V\QRYLRF\WHVZHUH WUHDWHGZLWK HLWKHU
$9;RU$7.KUVLQLQGLFDWHGFRQFHQWUDWLRQV$&RU0%SULRUWRVWLPXODWLRQZLWK71)QJP/IRUKUV$&RU
LQGLFDWHGWLPHV%$QDO\VLVRIUHOHDVHG>+@$$$%RU3*(&ZDVSHUIRUPHGDVGHVFULEHGLQWKH0HWKRGVVHFWLRQ3UHVHQWHG
YDOXHV DUHPHDQ  6' RI 71)LQGXFHG UHOHDVH FRPSDUHG WR XQWUHDWHG FRQWURO VDPSOHV LQ RQH UHSUHVHQWDWLYH RI DW OHDVW WKUHH
LQGHSHQGHQW H[SHULPHQWV SHUIRUPHG LQ GXSOLFDWHV 3*( RU WULSOLFDWHV >+@$$ $$ UHOHDVH OHYHOV IRU XQWUHDWHG VDPSOHV DUH
LQGLFDWHGE\DGDVKOLQHLQ%6\QRYLRF\WHVZHUHVWLPXODWHGZLWK71)QJP/IRUKRXUVSULRUWRO\VLVDQGGHWHFWLRQRILQYLWUR
F3/$ĮHQ]\PHDFWLYLW\DVGHVFULEHGLQWKH0HWKRGVVHFWLRQ'3UHVHQWHGYDOXHVDUHPHDQ6'RILQYLWURF3/$ĮDFWLYLW\LQ
RQHUHSUHVHQWDWLYHRIDWOHDVWWKUHHLQGHSHQGHQWH[SHULPHQWVSHUIRUPHGLQGXSOLFDWHV6WDWLVWLFDOVLJQLILFDQFHLVLQGLFDWHGDVIROORZV
$SZKHQFRPSDUHGWRXQWUHDWHGFRQWUROYDOXHVS$9;DQG͞S$7.ZKHQFRPSDUHGWR71)VWLPXODWHG
FRQWUROYDOXHV%SZKHQFRPSDUHGWRXQWUHDWHGFRQWUROYDOXHVSZKHQFRPSDUHGWR71)VWLPXODWHGFRQWUROYDOXHV
&SSZKHQFRPSDUHGWRXQWUHDWHGVDPSOHVDQGSZKHQFRPSDUHGWR71)VWLPXODWHGDQGFRQWUROYDOXHV
'SZKHQFRPSDUHGWRXQWUHDWHGFHOOO\VDWHVSZKHQFRPSDUHGWRXQWUHDWHGRU71)VWLPXODWHGFHOOO\VDWHVZLWKRXW
LQKLELWRU
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UHJXODWLQJ V\QRYLRF\WH H[SUHVVLRQ RI NH\ PHGLDWRUV RI ERQH
DQG FDUWLODJH GHVWUXFWLRQ DQJLRJHQHVLV DQG UHFUXLWPHQW RI
LPPXQHFHOOVDORQJZLWKWKHDYDLODELOLW\RI$$DQGVXEVHTXHQW
3*(SURGXFWLRQ
)LJXUH 3URSRVHG71)LQGXFHGDQGF3/$ĮGHSHQGHQW
VLJQDOLQJ LQ V\QRYLRF\WHV  71) LV D SRZHUIXO LQGXFHU RI
LQIODPPDWLRQ DQG MRLQW GHVWUXFWLRQ LQ 5$ ,Q WKH 6:
V\QRYLRF\WH PRGHO V\VWHP 71) LQGXFHV DFWLYDWLRQ RI WKH
F3/$ĮHQ]\PH WR UHOHDVH$$ IURPPHPEUDQHV SUHVXPDEO\
WKURXJK ELQGLQJ WR LWV UHFHSWRUV 71) UHFHSWRU  DQG 71)
UHFHSWRU  71)571)5 $$ UHOHDVHG E\ F3/$Į LV
PHWDEROL]HG E\ &2; WR 3*( D FRPPRQO\ UHFRJQL]HG
LQGXFHURILQIODPPDWLRQ7KH71)LQGXFHG$$FDVFDGHFDQEH
VHOIUHLQIRUFHG E\ WUDQVFULSWLRQDO UHJXODWLRQ RI &2; DQG
3/$*$ JHQHV 003 DQG ,/ DUH FHQWUDO HIIHFWRUV LQ 5$
WKURXJK FDUWLODJH GHVWUXFWLRQ 003 DQJLRJHQHVLV DQG
DWWUDFWLRQ RI LPPXQH FHOOV ,/ F3/$Į UHJXODWHV 71)
LQGXFHG H[SUHVVLRQ RI 003 DQG ,/ RQ WUDQVFULSWLRQDO DQG
SURWHLQ OHYHOV &RQVHTXHQWO\ F3/$Į IXQFWLRQV WR FRRUGLQDWH
MRLQWGHVWUXFWLYHDQGLQIODPPDWRU\SURFHVVHVLQV\QRYLRF\WHV
GRLMRXUQDOSRQHJ
2XU UHVXOWV GHPRQVWUDWH WKDW $9; HIILFLHQWO\ DQG
SHUVLVWHQWO\ UHGXFHV $$UHOHDVH DQG KHQFH WKH DYDLODELOLW\ RI
VXEVWUDWH IRU SURLQIODPPDWRU\ HLFRVDQRLG SURGXFWLRQ LQ
V\QRYLRF\WHV)LJXUH:HKDYHSUHYLRXVO\GHPRQVWUDWHGWKDW
$9; LV D SRWHQW LQKLELWRU RI UHFRPELQDQW F3/$Į HQ]\PH
DFWLYLW\ LQ YLWUR >@ DQG WKDW$9;HIILFLHQWO\ LQKLELWV3*(
SURGXFWLRQ LQ ,/ȕ VWLPXODWHG UDW PHVDQJLDO FHOOV +HUH ZH
SURYLGHSURRIRISULQFLSOHWKDW$9;SRWHQWO\LQKLELWVF3/$Į
DVZHIRUWKHILUVWWLPHGHPRQVWUDWHWKDW$9;LVDQLQKLELWRU
RI F3/$Į HQ]\PH DFWLYLW\ LQ V\QRYLRF\WHV )LJXUH '
$QDORJRXV HIIHFWV RI F3/$Į LQKLELWLRQ RI HQ]\PH DFWLYLW\
F\WRNLQHLQGXFHG $$ UHOHDVH 3*( SURGXFWLRQ DQG JHQH
H[SUHVVLRQKDVSUHYLRXVO\EHHQGHPRQVWUDWHGZLWKWKUHHRWKHU
FKHPLFDO LQKLELWRUV UHVHPEOLQJ $9; DQG $7. LQ FKHPLFDO
VWUXFWXUH 0$)3 DQG WKH WULIOXRURPHWK\O NHWRQH DQDORJXH RI
(3$ (3$&2&) >±@ %DVHG RQ WKHVH UHVXOWV DQG WKH
KHUHLQ UHSRUWHG REVHUYDWLRQV RQ WKH HIIHFWV RI $9; DQG
$7. LQ RXU PRGHO V\VWHP ZH SRVWXODWH WKDW WKH REVHUYHG
HIIHFWV RI $9; DUH GXH WR LQKLELWLRQ RI F3/$Į HQ]\PH
DFWLYLW\
7KHLPSRUWDQWUROHRI3*(LQSURSDJDWLQJLQIODPPDWLRQDQG
SDLQ LV FRPPRQO\ UHFRJQL]HG DV UHIOHFWHG E\ WKH HIIHFWLYH
V\PSWRPUHOLHIRISDLQDQGVWLIIQHVVE\16$,'WUHDWPHQWLQ5$
SDWLHQWV >@ 7KH KLJKO\ SOHLRWURSLF 3*( H[KLELWV D ZLGH
UDQJH RI ELRORJLFDO DFWLRQV >@ DQG LV DOVR SURSRVHG WR EH D
FHQWUDO IDFWRU LQ ERQH DQG FDUWLODJH UHVRUSWLRQ LQ DUWKULWLV
WKURXJK UHJXODWLRQ RI RVWHRFODVW DFWLYLW\ DQG H[SUHVVLRQ RI
F\WRNLQHV DQG003V LQ YDULRXV PRGHO V\VWHPV >±@ 7KH
YHUVDWLOHHIIHFWVRI3*(IXUWKHU LQFOXGHSURPRWLRQRI LPPXQH
FHOO LQIOX[ WR LQIODPHG WLVVXH DQG DQJLRJHQHVLV >@ $V
V\QRYLRF\WHVDUHLPSRUWDQWSURPRWHUVRILQIODPPDWLRQDQGMRLQW
GHVWUXFWLRQLQ5$WKHUHGXFHG3*(SURGXFWLRQE\$9;LQ
WKHVHFHOOVVXSSRUWVDNH\UROHIRUF3/$ĮLQ5$SDWKRJHQHVLV
2XU UHVXOWV IXUWKHU LPSO\ WKDW UHGXFHG 3*( V\QWKHVLV LQ
UHVSRQVH WR F3/$Į LQKLELWRUVPD\EH VHOIUHLQIRUFHG WKURXJK
WUDQVFULSWLRQDO UHJXODWLRQ RI WKH &2; DQG 3/$*$ JHQHV
)LJXUH'7UDQVFULSWLRQDOUHJXODWLRQRI&2;E\F3/$ĮKDV
SUHYLRXVO\ EHHQ VKRZQ LQPXULQHPRGHO V\VWHPV >@ DQG
RXUH[SHULPHQWVVXJJHVW WKDW WKLVPHFKDQLVPPLJKWEHDFWLYH
DOVRLQKXPDQV\QRYLRF\WHV7KHGHFUHDVHLQ3/$*$P51$
LQ UHVSRQVH WR F3/$Į LQKLELWLRQ LV WR RXU NQRZOHGJHDQRYHO
ILQGLQJ ,W PD\ VXJJHVW D IHHGEDFN ORRS IURP F3/$Į
HQ]\PDWLF DFWLYLW\ WKURXJK WUDQVFULSWLRQDO UHJXODWLRQ RI WKH
3/$*$JHQHLQUHVSRQVHWR71)LQV\QRYLRF\WHV)HHGEDFN
VLJQDOLQJ ZKHUH HQ]\PDWLF DFWLYLW\ RI F3/$Į LV UHTXLUHG WR
UHJXODWH LWV RZQJHQH LQGXFWLRQ LV SUHYLRXVO\ UHSRUWHG LQ OXQJ
ILEUREODVWV LQ UHVSRQVH WR ,/ȕ VWLPXODWLRQ >@ 7KLV SRVVLEOH
DXWRUHJXODWLRQ LQ UHVSRQVH WR SURLQIODPPDWRU\ VWLPXOL
SUHVHQWVDSRWHQWLDOVHOIUHLQIRUFLQJLPSDFWRILQKLELWLQJF3/$Į
HQ]\PHDFWLYLW\
$VGHJUDGDWLRQRIFDUWLODJHDQGERQHDUHPDMRUKDOOPDUNVRI
5$ GLVUXSWLRQ RI WKHVH GHVWUXFWLYH SURFHVVHV UHSUHVHQWV D
FHQWUDO WKHUDSHXWLF REMHFWLYH 003 ZLWK LWV ZLGH UDQJH RI
VXEVWUDWH VSHFLILFLW\ DQG DELOLW\ WR DFWLYDWH RWKHU 003V LV
HVVHQWLDO LQ 5$ FDUWLODJH GHJUDGDWLRQ >@ DQG FRUUHODWH ZLWK
GLVHDVHDFWLYLW\DQG LQIODPPDWLRQPDUNHUV LQ5$SDWLHQWV >@
:H LGHQWLI\ F3/$Į DV D SRVVLEOH UHJXODWRU RI 003
H[SUHVVLRQ LQ KXPDQ V\QRYLRF\WHV )LJXUH $ DQG & 7KLV
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FRUUHODWHV ZLWK UHSRUWHG ILQGLQJV IURP PXULQH DUWKULWLV >@
VXJJHVWLQJWKDWF3/$ĮLVDUHJXODWRURIFDUWLODJHGHJUDGDWLRQ
LQ5$$QJLRJHQHVLVDQGWKHFRQWLQXRXVLQIOX[RILPPXQHFHOOV
WR WKH LQIODPHG V\QRYLXPDUH LPSRUWDQW SURFHVVHV GULYLQJ WKH
LQIODPPDWLRQLQ5$MRLQWVF3/$ĮLVSURSRVHGWREHDUHJXODWRU
RIQHXWURSKLO UHFUXLWPHQWDQG LQIODPPDWLRQ LQPXULQHFROODJHQ
LQGXFHG DUWKULWLV >@ DQG KDV EHHQ IRXQG WR UHJXODWH
H[SUHVVLRQ RI WKH FKHPRWDFWLF DQG DQJLRJHQLF IDFWRU ,/ LQ
KXPDQ OXQJ ILEUREODVWV >@ :H VKRZ WKDW F3/$Į HQ]\PH
DFWLYLW\PLJKW EH LQYROYHG LQ UHJXODWLQJ ,/ SURGXFWLRQ DOVR LQ
KXPDQ V\QRYLRF\WHV )LJXUH % DQG & HPSKDVL]LQJ WKH
SRWHQWLDOELRORJLFDOUHOHYDQFHRIF3/$ĮLQV\QRYLWLV
*LYHQWKHFRPSOH[LW\RI71)VLJQDOLQJQHWZRUNVIRFXVLQJRQ
DQ LQWUDFHOOXODU WKHUDSHXWLF WDUJHW GRZQVWUHDP WKH 71)
UHFHSWRUPD\VKRZUHGXFHGDGYHUVHHIIHFWVFRPSDUHGWR71)
EORFNLQJ WKHUDS\ DVPDQ\ NH\ KRVW GHIHQVHPHFKDQLVPV DUH
QRW WDUJHWHG $FFRUGLQJO\ D PRGXODWLRQ RI F3/$Į HQ]\PH
DFWLYLW\ E\ VSHFLILF F3/$Į LQKLELWRUV DQG VXEVHTXHQWO\
QRUPDOL]LQJGRZQVWUHDPVLJQDOLQJPD\UHSUHVHQWDQDOWHUQDWLYH
RU VXSSOHPHQW WR FXUUHQW WKHUDSHXWLF VWUDWHJLHV IRU 5$
WUHDWPHQW ,QGHHGF3/$Į LVH[SUHVVHG LQ5$V\QRYLXP>@
DQGKDVEHHQVKRZQWRSOD\DQLPSRUWDQWUROHLQ LQIODPPDWLRQ
DQGLQVHYHUDODQLPDOPRGHOVRIDUWKULWLV>±@)XUWKHUPRUH
LQKLELWRUV RI F3/$Į LQFOXGLQJ $7. DQG S\UUR[\SKHQH
DPHOLRUDWHYDULRXV LQIODPPDWRU\FRQGLWLRQV LQFOXGLQJFROODJHQ
LQGXFHG DUWKULWLV LQ PLFH >@ 2XU UHVXOWV H[SDQG WKH
XQGHUVWDQGLQJ RI F3/$Į DV D SRVVLEOH UHJXODWRU RI
LQIODPPDWRU\ DQG MRLQW GHVWUXFWLYH SURFHVVHV LQ KXPDQ
V\QRYLRF\WHVWKURXJKUHJXODWLRQRI003,/DQG3*(
7DNHQ WRJHWKHUZHGHPRQVWUDWH WKDWF3/$ĮPD\KDYHDQ
LPSRUWDQWUROH LQUHJXODWLQJ71)LQGXFHG LQWUDFHOOXODUVLJQDOLQJ
LQV\QRYLRF\WHV+HQFHRXU UHVXOWVVXJJHVW WKDWF3/$ĮPD\
EH LQYROYHG LQ ERWK LQIODPPDWRU\ DQJLRJHQLF DQG WLVVXH
GHVWUXFWLYH SURFHVVHV DQG PD\ KHQFH EH D SURPLVLQJ
WKHUDSHXWLFWDUJHWWRUHGXFHLQIODPPDWLRQDQGGLVFRPIRUWSDLQ
UHGXFHGIXQFWLRQDOLW\DQGPRELOLW\DVVRFLDWHGZLWK5$
$FNQRZOHGJHPHQWV
7KHDXWKRUVZLVKWRWKDQN6LPRQH%DO]HU+DQQD0DMD7XQVHW
0DUL6 WKHUDQG7KX\1JX\HQIRUH[FHOOHQWWHFKQLFDOVXSSRUW
$XWKRU&RQWULEXWLRQV
&RQFHLYHG DQG GHVLJQHG WKH H[SHULPHQWV $-) %- 506
3HUIRUPHG WKHH[SHULPHQWV506$-).-$QDO\]HG WKHGDWD
506 $-) %- &RQWULEXWHG UHDJHQWVPDWHULDOVDQDO\VLV WRROV
%-:URWHWKHPDQXVFULSW506$-)%-
5HIHUHQFHV
 +DUULV (' %XGG5& )LUHVWHLQ*6*HQRYHVH0& 6HUJHQW -6 HW DO
 .HOOH\V WH[WERRN RI UKHXPDWRORJ\  9ROXPH ,  HG
3KLODGHOSKLD(OVHYLHUV6DXQGHUV
 %DUWRN%)LUHVWHLQ*6)LEUREODVWOLNHV\QRYLRF\WHVNH\HIIHFWRU
FHOOVLQUKHXPDWRLGDUWKULWLV,PPXQRO5HYGRLM
[3XE0HG
 &KR\ (+6 3DQD\L *6  &\WRNLQH 3DWKZD\V DQG -RLQW
,QIODPPDWLRQLQ5KHXPDWRLG$UWKULWLV1(QJO-0HGGRL
1(-03XE0HG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Doctoral theses 
in Biology

Doctoral theses in Biology 
Norwegian University of Science and Technology 
Department of Biology 
 
 Year Name Degree Title
  1974 Tor-Henning Iversen Dr. 
philos 
Botany 
The roles of statholiths, auxin transport, and auxin 
metabolism in root gravitropism 
 1978 Tore Slagsvold Dr. 
philos 
Zoology 
Breeding events of birds in relation to spring 
temperature and environmental phenology 
 1978 Egil Sakshaug Dr.philos 
Botany 
"The influence of environmental factors on the 
chemical composition of cultivated and natural 
populations of marine phytoplankton" 
  1980 Arnfinn Langeland Dr. 
philos 
Zoology 
Interaction between fish and zooplankton populations 
and their effects on the material utilization in a 
freshwater lake 
 1980 Helge Reinertsen Dr. 
philos 
Botany 
The effect of lake fertilization on the dynamics and 
stability of a limnetic ecosystem with special 
reference to the phytoplankton 
 1982 Gunn Mari Olsen Dr. 
scient 
Botany 
Gravitropism in roots of Pisum sativum and 
Arabidopsis thaliana 
 1982 Dag Dolmen Dr. 
philos 
Zoology 
Life aspects of two sympartic species of newts 
(Triturus, Amphibia) in Norway, with special 
emphasis on their ecological niche segregation 
 1984 Eivin Røskaft Dr. 
philos 
Zoology 
Sociobiological studies of the rook Corvus frugilegus 
 1984 Anne Margrethe 
Cameron 
Dr. 
scient 
Botany 
Effects of alcohol inhalation on levels of circulating 
testosterone, follicle stimulating hormone and 
luteinzing hormone in male mature rats 
 1984 Asbjørn Magne 
Nilsen 
Dr. 
scient 
Botany 
Alveolar macrophages from expectorates – 
Biological monitoring of workers exosed to 
occupational air pollution. An evaluation of the AM-
test 
 1985 Jarle Mork Dr. 
philos 
Zoology 
Biochemical genetic studies in fish 
 1985 John Solem Dr. 
philos 
Zoology 
Taxonomy, distribution and ecology of caddisflies 
(Trichoptera) in the Dovrefjell mountains 
 1985 Randi E. Reinertsen Dr. 
philos 
Zoology 
Energy strategies in the cold: Metabolic and 
thermoregulatory adaptations in small northern birds 
 1986 Bernt-Erik Sæther Dr. 
philos 
Zoology 
Ecological and evolutionary basis for variation in 
reproductive traits of some vertebrates: A 
comparative approach 
 1986 Torleif Holthe Dr. 
philos 
Zoology 
Evolution, systematics, nomenclature, and 
zoogeography in the polychaete orders 
Oweniimorpha and Terebellomorpha, with special 
reference to the Arctic and Scandinavian fauna 
 1987 Helene Lampe Dr. 
scient 
The function of bird song in mate attraction and 
territorial defence, and the importance of song 
Zoology repertoires 
 1987 Olav Hogstad Dr. 
philos 
Zoology 
Winter survival strategies of the Willow tit Parus 
montanus 
 1987 Jarle Inge Holten Dr. 
philos 
Botany 
Autecological investigations along a coust-inland 
transect at Nord-Møre, Central Norway 
 1987 Rita Kumar Dr. 
scient 
Botany 
Somaclonal variation in plants regenerated from cell 
cultures of Nicotiana sanderae and Chrysanthemum 
morifolium 
 1987 Bjørn Åge 
Tømmerås 
Dr. 
scient. 
Zoolog 
Olfaction in bark beetle communities: Interspecific 
interactions in regulation of colonization density, 
predator - prey relationship and host attraction 
 1988 Hans Christian 
Pedersen 
Dr. 
philos 
Zoology 
Reproductive behaviour in willow ptarmigan with 
special emphasis on territoriality and parental care 
 1988 Tor G. Heggberget Dr. 
philos 
Zoology 
Reproduction in Atlantic Salmon (Salmo salar): 
Aspects of spawning, incubation, early life history 
and population structure 
 1988 Marianne V. Nielsen Dr. 
scient 
Zoology 
The effects of selected environmental factors on 
carbon allocation/growth of larval and juvenile 
mussels (Mytilus edulis) 
 1988 Ole Kristian Berg Dr. 
scient 
Zoology 
The formation of landlocked Atlantic salmon (Salmo 
salar L.) 
 1989 John W. Jensen Dr. 
philos 
Zoology 
Crustacean plankton and fish during the first decade 
of the manmade Nesjø reservoir, with special 
emphasis on the effects of gill nets and salmonid 
growth 
 1989 Helga J. Vivås Dr. 
scient 
Zoology 
Theoretical models of activity pattern and optimal 
foraging: Predictions for the Moose Alces alces 
 1989 Reidar Andersen Dr. 
scient 
Zoology 
Interactions between a generalist herbivore, the 
moose Alces alces, and its winter food resources: a 
study of behavioural variation 
 1989 Kurt Ingar Draget Dr. 
scient 
Botany 
Alginate gel media for plant tissue culture 
 
 1990 Bengt Finstad Dr. 
scient 
Zoology 
Osmotic and ionic regulation in Atlantic salmon, 
rainbow trout and Arctic charr: Effect of temperature, 
salinity and season 
 1990 Hege Johannesen Dr. 
scient 
Zoology 
Respiration and temperature regulation in birds with 
special emphasis on the oxygen extraction by the 
lung 
 1990 Åse Krøkje Dr. 
scient 
Botany 
The mutagenic load from air pollution at two work-
places with PAH-exposure measured with Ames 
Salmonella/microsome test 
 1990 Arne Johan Jensen Dr. 
philos 
Zoology 
Effects of water temperature on early life history, 
juvenile growth and prespawning migrations of 
Atlantic salmion (Salmo salar) and brown trout 
(Salmo trutta): A summary of studies in Norwegian 
streams 
 1990 Tor Jørgen Almaas Dr. 
scient 
Zoology 
Pheromone reception in moths: Response 
characteristics of olfactory receptor neurons to intra- 
and interspecific chemical cues 
 1990 Magne Husby Dr. Breeding strategies in birds: Experiments with the 
scient 
Zoology 
Magpie Pica pica 
 1991 Tor Kvam Dr. 
scient 
Zoology 
Population biology of the European lynx (Lynx lynx) 
in Norway 
 1991 Jan Henning L'Abêe 
Lund 
Dr. 
philos 
Zoology 
Reproductive biology in freshwater fish, brown trout 
Salmo trutta and roach Rutilus rutilus in particular 
 1991 Asbjørn Moen Dr. 
philos 
Botany 
The plant cover of the boreal uplands of Central 
Norway. I. Vegetation ecology of Sølendet nature 
reserve; haymaking fens and birch woodlands 
 1991  Else Marie Løbersli Dr. 
scient 
Botany 
Soil acidification and metal uptake in plants 
 1991 Trond Nordtug Dr. 
scient 
Zoology 
Reflctometric studies of photomechanical adaptation 
in superposition eyes of arthropods 
 1991 Thyra Solem Dr. 
scient 
Botany 
Age, origin and development of blanket mires in 
Central Norway 
 1991 Odd Terje Sandlund Dr. 
philos 
Zoology 
The dynamics of habitat use in the salmonid genera 
Coregonus and Salvelinus: Ontogenic niche shifts 
and polymorphism 
 1991 Nina Jonsson Dr. 
philos 
Aspects of migration and spawning in salmonids 
 1991 Atle Bones Dr. 
scient 
Botany 
Compartmentation and molecular properties of 
thioglucoside glucohydrolase (myrosinase) 
 1992 Torgrim Breiehagen Dr. 
scient 
Zoology 
Mating behaviour and evolutionary aspects of the 
breeding system of two bird species: the Temminck's 
stint and the Pied flycatcher 
 1992 Anne Kjersti Bakken Dr. 
scient 
Botany 
The influence of photoperiod on nitrate assimilation 
and nitrogen status in timothy (Phleum pratense L.) 
 1992 
 
Tycho Anker-Nilssen Dr. 
scient 
Zoology 
Food supply as a determinant of reproduction and 
population development in Norwegian Puffins 
Fratercula arctica 
 1992 Bjørn Munro Jenssen Dr. 
philos 
Zoology 
Thermoregulation in aquatic birds in air and water: 
With special emphasis on the effects of crude oil, 
chemically treated oil and cleaning on the thermal 
balance of ducks 
 1992 Arne Vollan Aarset Dr. 
philos 
Zoology 
The ecophysiology of under-ice fauna: Osmotic 
regulation, low temperature tolerance and 
metabolism in polar crustaceans. 
 1993 Geir Slupphaug Dr. 
scient 
Botany 
Regulation and expression of uracil-DNA 
glycosylase and O6-methylguanine-DNA 
methyltransferase in mammalian cells 
 1993 Tor Fredrik Næsje Dr. 
scient 
Zoology 
Habitat shifts in coregonids. 
 1993 Yngvar Asbjørn 
Olsen 
Dr. 
scient 
Zoology 
Cortisol dynamics in Atlantic salmon, Salmo salar 
L.: Basal and stressor-induced variations in plasma 
levels ans some secondary effects. 
 1993 Bård Pedersen Dr. 
scient 
Botany 
Theoretical studies of life history evolution in 
modular and clonal organisms 
 1993 Ole Petter Thangstad Dr. 
scient 
Botany 
Molecular studies of myrosinase in Brassicaceae 
 1993 Thrine L. M. 
Heggberget 
Dr. 
scient 
Zoology 
Reproductive strategy and feeding ecology of the 
Eurasian otter Lutra lutra. 
 1993 Kjetil Bevanger Dr. 
scient. 
Zoology 
Avian interactions with utility structures, a biological 
approach. 
 1993 Kåre Haugan Dr. 
scient 
Bothany 
Mutations in the replication control gene trfA of the 
broad host-range plasmid RK2 
 1994 Peder Fiske Dr. 
scient. 
Zoology 
Sexual selection in the lekking great snipe (Gallinago 
media): Male mating success and female behaviour at 
the lek 
 1994 Kjell Inge Reitan Dr. 
scient 
Botany 
Nutritional effects of algae in first-feeding of marine 
fish larvae 
 1994 Nils Røv Dr. 
scient 
Zoology 
Breeding distribution, population status and 
regulation of breeding numbers in the northeast-
Atlantic Great Cormorant Phalacrocorax carbo 
carbo 
 1994 Annette-Susanne 
Hoepfner 
Dr. 
scient 
Botany 
Tissue culture techniques in propagation and 
breeding of Red Raspberry (Rubus idaeus L.) 
 1994 Inga Elise Bruteig Dr. 
scient 
Bothany 
Distribution, ecology and biomonitoring studies of 
epiphytic lichens on conifers 
 1994 Geir Johnsen Dr. 
scient 
Botany 
Light harvesting and utilization in marine 
phytoplankton: Species-specific and photoadaptive 
responses 
 1994 Morten Bakken Dr. 
scient 
Zoology 
 
Infanticidal behaviour and reproductive performance 
in relation to competition capacity among farmed 
silver fox vixens, Vulpes vulpes 
 1994 Arne Moksnes Dr. 
philos 
Zoology 
Host adaptations towards brood parasitism by the 
Cockoo 
 1994 Solveig Bakken Dr. 
scient 
Bothany 
Growth and nitrogen status in the moss Dicranum 
majus Sm. as influenced by nitrogen supply 
 1994 Torbjørn Forseth Dr. 
scient 
Zoology 
Bioenergetics in ecological and life history studies of 
fishes. 
 1995 Olav Vadstein Dr. 
philos 
Botany 
The role of heterotrophic planktonic bacteria in the 
cycling of phosphorus in lakes: Phosphorus 
requirement, competitive ability and food web 
interactions 
 1995 Hanne Christensen Dr. 
scient 
Zoology 
Determinants of Otter Lutra lutra distribution in 
Norway: Effects of harvest, polychlorinated 
biphenyls (PCBs), human population density and 
competition with mink Mustela vision 
 1995 Svein Håkon 
Lorentsen 
Dr. 
scient 
Zoology 
Reproductive effort in the Antarctic Petrel 
Thalassoica antarctica; the effect of parental body 
size and condition 
 1995 Chris Jørgen Jensen Dr. The surface electromyographic (EMG) amplitude as 
scient 
Zoology 
an estimate of upper trapezius muscle activity 
 1995 Martha Kold 
Bakkevig 
Dr. 
scient 
Zoology 
The impact of clothing textiles and construction in a 
clothing system on thermoregulatory responses, 
sweat accumulation and heat transport 
 1995 Vidar Moen Dr. 
scient 
Zoology 
Distribution patterns and adaptations to light in newly 
introduced populations of Mysis relicta and 
constraints on Cladoceran and Char populations 
 1995 Hans Haavardsholm 
Blom 
Dr. 
philos 
Bothany 
A revision of the Schistidium apocarpum complex in 
Norway and Sweden 
 1996 Jorun Skjærmo Dr. 
scient 
Botany 
Microbial ecology of early stages of cultivated 
marine fish; inpact fish-bacterial interactions on 
growth and survival of larvae 
 1996 Ola Ugedal Dr. 
scient 
Zoology 
Radiocesium turnover in freshwater fishes 
 1996 Ingibjørg 
Einarsdottir 
Dr. 
scient 
Zoology 
Production of Atlantic salmon (Salmo salar) and 
Arctic charr (Salvelinus alpinus): A study of some 
physiological and immunological responses to 
rearing routines 
 1996 Christina M. S. 
Pereira 
Dr. 
scient 
Zoology 
Glucose metabolism in salmonids: Dietary effects 
and hormonal regulation 
 1996 Jan Fredrik Børseth Dr. 
scient 
Zoology 
The sodium energy gradients in muscle cells of 
Mytilus edulis and the effects of organic xenobiotics 
 1996 Gunnar Henriksen Dr. 
scient 
Zoology 
Status of Grey seal Halichoerus grypus and Harbour 
seal Phoca vitulina in the Barents sea region 
 1997 Gunvor Øie Dr. 
scient 
Bothany 
Eevalution of rotifer Brachionus plicatilis quality in 
early first feeding of turbot Scophtalmus maximus L. 
larvae 
 1997 Håkon Holien Dr. 
scient 
Botany 
Studies of lichens in spurce forest of Central Norway. 
Diversity, old growth species and the relationship to 
site and stand parameters 
 1997 Ole Reitan  Dr. 
scient. 
Zoology 
Responses of birds to habitat disturbance due to 
damming 
 1997 Jon Arne Grøttum  Dr. 
scient. 
Zoology 
Physiological effects of reduced water quality on fish 
in aquaculture 
 1997 Per Gustav 
Thingstad  
Dr. 
scient. 
Zoology 
Birds as indicators for studying natural and human-
induced variations in the environment, with special 
emphasis on the suitability of the Pied Flycatcher 
 1997 Torgeir Nygård  Dr. 
scient 
Zoology 
Temporal and spatial trends of pollutants in birds in 
Norway: Birds of prey and Willow Grouse used as 
Biomonitors 
 1997 Signe Nybø  Dr. 
scient. 
Zoology 
Impacts of long-range transported air pollution on 
birds with particular reference to the dipper Cinclus 
cinclus in southern Norway 
 1997 Atle Wibe  Dr. 
scient. 
Zoology 
Identification of conifer volatiles detected by receptor 
neurons in the pine weevil (Hylobius abietis), 
analysed by gas chromatography linked to 
electrophysiology and to mass spectrometry 
 1997 Rolv Lundheim  Dr. Adaptive and incidental biological ice nucleators    
scient 
Zoology 
 1997 Arild Magne Landa Dr. 
scient 
Zoology 
Wolverines in Scandinavia: ecology, sheep 
depredation and conservation 
 1997 Kåre Magne Nielsen Dr. 
scient 
Botany 
An evolution of possible horizontal gene transfer 
from plants to sail bacteria by studies of natural 
transformation in Acinetobacter calcoacetius 
 1997 Jarle Tufto  Dr. 
scient 
Zoology 
Gene flow and genetic drift in geographically 
structured populations: Ecological, population 
genetic, and statistical models 
 1997 Trygve Hesthagen  Dr. 
philos 
Zoology 
Population responces of Arctic charr (Salvelinus 
alpinus (L.)) and brown trout (Salmo trutta L.) to 
acidification in Norwegian inland waters 
 1997 Trygve Sigholt  Dr. 
philos 
Zoology 
Control of  Parr-smolt transformation and seawater 
tolerance in farmed Atlantic Salmon (Salmo salar) 
Effects of photoperiod, temperature, gradual seawater 
acclimation, NaCl and betaine in the diet 
 1997 Jan Østnes  Dr. 
scient 
Zoology 
Cold sensation in adult and neonate birds 
 1998 Seethaledsumy 
Visvalingam 
Dr. 
scient 
Botany 
Influence of environmental factors on myrosinases 
and myrosinase-binding proteins 
 1998 Thor Harald Ringsby Dr. 
scient 
Zoology 
Variation in space and time: The biology of a House 
sparrow metapopulation 
 1998 Erling Johan Solberg Dr. 
scient. 
Zoology 
Variation in population dynamics and life history in a 
Norwegian moose (Alces alces) population: 
consequences of harvesting in a variable environment 
 1998 Sigurd Mjøen 
Saastad 
Dr. 
scient 
Botany 
Species delimitation and phylogenetic relationships 
between the Sphagnum recurvum complex 
(Bryophyta): genetic variation and phenotypic 
plasticity 
 1998 Bjarte Mortensen Dr. 
scient 
Botany 
Metabolism of volatile organic chemicals (VOCs) in 
a head liver S9 vial  equilibration system in vitro 
 1998 Gunnar Austrheim Dr. 
scient 
Botany 
Plant biodiversity and land use in subalpine 
grasslands. – A conservtaion biological approach 
 1998 Bente Gunnveig 
Berg 
Dr. 
scient 
Zoology 
Encoding of pheromone information in two related 
moth species 
 1999 Kristian Overskaug Dr. 
scient 
Zoology 
Behavioural and morphological characteristics in 
Northern Tawny Owls Strix aluco: An intra- and 
interspecific comparative approach 
 1999 Hans Kristen 
Stenøien 
Dr. 
scient 
Bothany 
Genetic studies of evolutionary processes in various 
populations of nonvascular plants (mosses, liverworts 
and hornworts) 
 1999 Trond Arnesen Dr. 
scient 
Botany 
Vegetation dynamics following trampling and 
burning in the outlying haylands at Sølendet, Central 
Norway 
 1999 Ingvar Stenberg Dr. 
scient 
Zoology 
Habitat selection, reproduction and survival in the 
White-backed Woodpecker Dendrocopos leucotos 
 1999 Stein Olle Johansen Dr. A study of driftwood dispersal to the Nordic Seas by 
scient 
Botany 
dendrochronology and wood anatomical analysis 
 1999 Trina Falck 
Galloway 
Dr. 
scient 
Zoology 
Muscle development and growth in early life stages 
of the Atlantic cod (Gadus morhua L.) and Halibut 
(Hippoglossus hippoglossus L.) 
 1999 Marianne Giæver Dr. 
scient 
Zoology 
Population genetic studies in three gadoid species: 
blue whiting (Micromisistius poutassou), haddock 
(Melanogrammus aeglefinus) and cod (Gradus 
morhua) in the North-East Atlantic 
 1999 Hans Martin Hanslin Dr. 
scient 
Botany 
The impact of environmental conditions of density 
dependent performance in the boreal forest 
bryophytes Dicranum majus, Hylocomium splendens, 
Plagiochila asplenigides, Ptilium crista-castrensis 
and Rhytidiadelphus lokeus 
 1999 Ingrid Bysveen 
Mjølnerød 
Dr. 
scient 
Zoology 
Aspects of population genetics, behaviour and 
performance of wild and farmed Atlantic salmon 
(Salmo salar) revealed by molecular genetic 
techniques 
 1999 Else Berit Skagen Dr. 
scient 
Botany 
The early regeneration process in protoplasts from 
Brassica napus hypocotyls cultivated under various 
g-forces 
 1999 Stein-Are Sæther Dr. 
philos 
Zoology 
Mate choice, competition for mates, and conflicts of 
interest in the Lekking Great Snipe 
 1999 Katrine Wangen 
Rustad 
Dr. 
scient 
Zoology 
Modulation of glutamatergic neurotransmission 
related to cognitive dysfunctions and Alzheimer’s 
disease 
 1999 Per Terje Smiseth Dr. 
scient 
Zoology 
Social evolution in monogamous families: 
mate choice and conflicts over parental care in the 
Bluethroat (Luscinia s. svecica) 
 1999 Gunnbjørn Bremset Dr. 
scient 
Zoology 
Young Atlantic salmon (Salmo salar L.) and Brown 
trout (Salmo trutta L.) inhabiting the deep pool 
habitat, with special reference to their habitat use, 
habitat preferences and competitive interactions 
 1999 Frode Ødegaard Dr. 
scient 
Zoology 
Host spesificity as parameter in estimates of 
arhrophod species richness 
 1999 Sonja Andersen Dr. 
scient 
Bothany 
Expressional and functional analyses of human, 
secretory phospholipase A2 
 2000 Ingrid Salvesen Dr. 
scient 
Botany 
Microbial ecology in early stages of marine fish: 
Development and evaluation of methods for 
microbial management in intensive larviculture 
  2000 Ingar Jostein Øien Dr. 
scient 
Zoology 
The Cuckoo (Cuculus canorus) and its host: 
adaptions and counteradaptions in a coevolutionary 
arms race 
 2000 Pavlos Makridis Dr. 
scient 
Botany 
Methods for the microbial econtrol of live food used 
for the rearing of marine fish larvae 
  2000 Sigbjørn Stokke Dr. 
scient 
Zoology 
Sexual segregation in the African elephant 
(Loxodonta africana) 
 2000 Odd A. Gulseth Dr. 
philos 
Zoology 
Seawater tolerance, migratory behaviour and growth 
of Charr, (Salvelinus alpinus), with emphasis on the 
high Arctic Dieset charr on Spitsbergen, Svalbard 
 2000 Pål A. Olsvik Dr. Biochemical impacts of Cd, Cu and Zn on brown 
scient 
Zoology 
trout (Salmo trutta) in two mining-contaminated 
rivers in Central Norway 
 2000 Sigurd Einum Dr. 
scient 
Zoology 
Maternal effects in fish: Implications for the 
evolution of breeding time and egg size 
 2001 Jan Ove Evjemo Dr. 
scient 
Zoology 
Production and nutritional adaptation of the brine 
shrimp Artemia sp. as live food organism for larvae 
of marine cold water fish species 
 2001 Olga Hilmo Dr. 
scient 
Botany 
Lichen response to environmental changes in the 
managed boreal forset systems 
 2001 Ingebrigt Uglem Dr. 
scient 
Zoology 
Male dimorphism and reproductive biology in 
corkwing wrasse (Symphodus melops L.) 
 2001 Bård Gunnar Stokke Dr. 
scient 
Zoology 
Coevolutionary adaptations in avian brood parasites 
and their hosts 
 2002 Ronny Aanes Dr. 
scient 
Spatio-temporal dynamics in Svalbard reindeer 
(Rangifer tarandus platyrhynchus) 
 2002 Mariann Sandsund Dr. 
scient 
Zoology 
Exercise- and cold-induced asthma. Respiratory and 
thermoregulatory responses 
 2002 Dag-Inge Øien Dr. 
scient 
Botany 
Dynamics of plant communities and populations in 
boreal vegetation influenced by scything at Sølendet, 
Central Norway 
 2002 Frank Rosell Dr. 
scient 
Zoology 
The function of scent marking in beaver (Castor 
fiber) 
 2002 Janne Østvang Dr. 
scient 
Botany 
The Role and Regulation of Phospholipase A2 in 
Monocytes During Atherosclerosis Development 
 2002 Terje Thun Dr.philos 
Biology 
Dendrochronological constructions of Norwegian 
conifer chronologies providing dating of historical 
material 
 2002 Birgit Hafjeld 
Borgen 
Dr. 
scient 
Biology 
Functional analysis of plant idioblasts (Myrosin cells) 
and their role in defense, development and growth 
 2002 Bård Øyvind Solberg Dr. 
scient 
Biology 
Effects of climatic change on the growth of 
dominating tree species along major environmental 
gradients 
 2002 Per Winge Dr. 
scient 
Biology 
The evolution of small GTP binding proteins in 
cellular organisms. Studies of RAC GTPases in 
Arabidopsis thaliana and the Ral GTPase from 
Drosophila melanogaster 
 2002 Henrik Jensen Dr. 
scient 
Biology 
Causes and consequenses of individual variation in 
fitness-related traits in house sparrows 
 2003 Jens Rohloff Dr. 
philos 
Biology 
Cultivation of herbs and medicinal plants in Norway 
– Essential oil production and quality control 
 2003 Åsa Maria O. 
Espmark Wibe 
Dr. 
scient 
Biology 
Behavioural effects of environmental pollution in 
threespine stickleback Gasterosteus aculeatur L. 
 2003 Dagmar Hagen Dr. 
scient 
Biology 
Assisted recovery of disturbed arctic and alpine 
vegetation – an integrated approach 
 2003 Bjørn Dahle Dr. 
scient 
Biology 
Reproductive strategies in Scandinavian brown bears 
 2003 Cyril Lebogang 
Taolo 
Dr. 
scient 
Biology 
Population ecology, seasonal movement and habitat 
use of the African buffalo (Syncerus caffer) in Chobe 
National Park, Botswana 
 2003 Marit Stranden Dr.scient 
Biology 
Olfactory receptor neurones specified for the same 
odorants in three related Heliothine species 
(Helicoverpa armigera, Helicoverpa assulta and 
Heliothis virescens) 
 2003 Kristian Hassel Dr.scient 
Biology 
Life history characteristics and genetic variation in an 
expanding species, Pogonatum dentatum 
 2003 David Alexander Rae Dr.scient 
Biology 
Plant- and invertebrate-community responses to 
species interaction and microclimatic gradients in 
alpine and Artic environments 
 2003 Åsa A Borg Dr.scient 
Biology 
Sex roles and reproductive behaviour in gobies and 
guppies: a female perspective 
 2003 Eldar Åsgard 
Bendiksen 
Dr.scient 
Biology 
Environmental effects on lipid nutrition of farmed 
Atlantic salmon (Salmo Salar L.) parr and smolt 
 2004 Torkild Bakken Dr.scient 
Biology 
A revision of Nereidinae (Polychaeta, Nereididae) 
 2004 Ingar Pareliussen Dr.scient 
Biology 
Natural and Experimental Tree Establishment in a 
Fragmented Forest, Ambohitantely Forest Reserve, 
Madagascar 
 2004 Tore Brembu Dr.scient 
Biology 
Genetic, molecular and functional studies of RAC 
GTPases and the WAVE-like regulatory protein 
complex in Arabidopsis thaliana 
 2004 Liv S. Nilsen Dr.scient 
Biology 
Coastal heath vegetation on central Norway; recent 
past, present state and future possibilities 
 2004 Hanne T. Skiri Dr.scient 
Biology 
Olfactory coding and olfactory learning of plant 
odours in heliothine moths. An anatomical, 
physiological and behavioural study of three related 
species (Heliothis virescens, Helicoverpa armigera 
and Helicoverpa assulta) 
 2004 Lene Østby Dr.scient 
Biology 
Cytochrome P4501A (CYP1A) induction and DNA 
adducts as biomarkers for organic pollution in the 
natural environment 
 2004 Emmanuel J. Gerreta Dr. 
philos 
Biology 
The Importance of Water Quality and Quantity in the 
Tropical Ecosystems, Tanzania 
 2004 Linda Dalen Dr.scient 
Biology 
Dynamics of Mountain Birch Treelines in the 
Scandes Mountain Chain, and Effects of Climate 
Warming 
 2004 Lisbeth Mehli Dr.scient 
Biology 
Polygalacturonase-inhibiting protein (PGIP) in 
cultivated strawberry (Fragaria x ananassa): 
characterisation and induction of the gene following 
fruit infection by Botrytis cinerea 
 2004 Børge Moe Dr.scient 
Biology 
Energy-Allocation in Avian Nestlings Facing Short-
Term Food Shortage 
 2005 Matilde Skogen 
Chauton 
Dr.scient 
Biology 
Metabolic profiling and species discrimination from 
High-Resolution Magic Angle Spinning NMR 
analysis of whole-cell samples 
 2005  Sten Karlsson Dr.scient 
Biology 
Dynamics of Genetic Polymorphisms 
 2005 Terje Bongard Dr.scient 
Biology 
Life History strategies, mate choice, and parental 
investment among Norwegians over a 300-year 
period 
 2005 Tonette Røstelien ph.d 
Biology 
Functional characterisation of olfactory receptor 
neurone types in heliothine moths 
 2005 Erlend Kristiansen Dr.scient 
Biology 
Studies on antifreeze proteins 
 2005 Eugen G. Sørmo Dr.scient 
Biology 
Organochlorine pollutants in grey seal (Halichoerus 
grypus) pups and their impact on plasma thyrid 
hormone and vitamin A concentrations 
 2005 Christian Westad Dr.scient 
Biology 
Motor control of the upper trapezius 
 2005 Lasse Mork Olsen ph.d 
Biology 
Interactions between marine osmo- and phagotrophs 
in different physicochemical environments 
 2005 Åslaug Viken ph.d 
Biology 
Implications of mate choice for the management of 
small populations 
 2005 Ariaya Hymete Sahle 
Dingle 
ph.d 
Biology 
Investigation of the biological activities and chemical 
constituents of selected Echinops spp. growing in 
Ethiopia 
 2005 Anders Gravbrøt 
Finstad 
ph.d 
Biology 
Salmonid fishes in a changing climate: The winter 
challenge 
 2005 Shimane Washington 
Makabu 
ph.d 
Biology 
Interactions between woody plants, elephants and 
other browsers in the Chobe Riverfront, Botswana 
 2005 Kjartan Østbye Dr.scient 
Biology 
The European whitefish Coregonus lavaretus (L.) 
species complex: historical contingency and adaptive 
radiation 
 2006 Kari Mette Murvoll ph.d 
Biology 
Levels and effects of persistent organic pollutans 
(POPs) in seabirds 
Retinoids and Į-tocopherol –  potential biomakers of 
POPs in birds?  
 2006 Ivar Herfindal Dr.scient 
Biology 
Life history consequences of environmental variation 
along ecological gradients in northern ungulates 
 2006 Nils Egil Tokle ph.d 
Biology 
Are the ubiquitous marine copepods limited by food 
or predation? Experimental and field-based studies 
with main focus on Calanus finmarchicus 
 2006 Jan Ove Gjershaug Dr.philos 
Biology 
Taxonomy and conservation status of some booted 
eagles in south-east Asia 
 2006 Jon Kristian Skei Dr.scient 
Biology 
Conservation biology and acidification problems in 
the breeding habitat of amphibians in Norway 
 2006 Johanna Järnegren ph.d 
Biology 
Acesta Oophaga and Acesta Excavata – a study of 
hidden biodiversity 
 2006 Bjørn Henrik Hansen ph.d 
Biology 
Metal-mediated oxidative stress responses in brown 
trout (Salmo trutta) from mining contaminated rivers 
in Central Norway 
 2006 Vidar Grøtan ph.d 
Biology 
Temporal and spatial effects of climate fluctuations 
on population dynamics of vertebrates 
 2006 Jafari R Kideghesho ph.d 
Biology 
Wildlife conservation and local land use conflicts in 
western Serengeti, Corridor Tanzania 
 2006 Anna Maria Billing ph.d 
Biology 
Reproductive decisions in the sex role reversed 
pipefish Syngnathus typhle: when and how to invest 
in reproduction 
 2006 Henrik Pärn ph.d 
Biology 
Female ornaments and reproductive biology in the 
bluethroat 
 2006 Anders J. Fjellheim ph.d 
Biology 
Selection and administration of probiotic bacteria to 
marine fish larvae 
 2006 P. Andreas Svensson ph.d 
Biology 
Female coloration, egg carotenoids and reproductive 
success: gobies as a model system 
 2007 Sindre A. Pedersen ph.d Metal binding proteins and antifreeze proteins in the 
Biology beetle Tenebrio molitor 
- a study on possible competition for the semi-
essential amino acid cysteine 
 2007 Kasper Hancke ph.d 
Biology 
Photosynthetic responses as a function of light and 
temperature: Field and laboratory studies on marine 
microalgae 
 2007 Tomas Holmern ph.d 
Biology 
Bushmeat hunting in the western Serengeti: 
Implications for community-based conservation 
 2007 Kari Jørgensen ph.d 
Biology 
Functional tracing of gustatory receptor neurons in 
the CNS and chemosensory learning in the moth 
Heliothis virescens 
 2007  Stig Ulland ph.d 
Biology 
Functional Characterisation of Olfactory Receptor 
Neurons in the Cabbage Moth, (Mamestra brassicae 
L.) (Lepidoptera, Noctuidae). Gas Chromatography 
Linked to Single Cell Recordings and Mass 
Spectrometry 
 2007 Snorre Henriksen ph.d 
Biology 
Spatial and temporal variation in herbivore resources 
at northern latitudes 
 2007 Roelof Frans May ph.d 
Biology 
Spatial Ecology of Wolverines in Scandinavia  
 
 2007 Vedasto Gabriel 
Ndibalema 
ph.d 
Biology 
Demographic variation, distribution and habitat use 
between wildebeest sub-populations in the Serengeti 
National Park, Tanzania 
 2007 Julius William 
Nyahongo 
ph.d 
Biology 
Depredation of Livestock by wild Carnivores and 
Illegal Utilization of Natural Resources by Humans 
in the Western Serengeti, Tanzania 
 2007 Shombe Ntaraluka 
Hassan 
ph.d 
Biology 
Effects of fire on large herbivores and their forage 
resources in Serengeti, Tanzania 
 2007 Per-Arvid Wold ph.d 
Biology 
Functional development and response to dietary 
treatment in larval Atlantic cod (Gadus morhua L.) 
Focus on formulated diets and early weaning 
 2007 Anne Skjetne 
Mortensen 
ph.d 
Biology 
Toxicogenomics of Aryl Hydrocarbon- and Estrogen 
Receptor Interactions in Fish: Mechanisms and 
Profiling of Gene Expression Patterns in Chemical 
Mixture Exposure Scenarios 
  2008 Brage Bremset 
Hansen 
ph.d 
Biology 
The Svalbard reindeer (Rangifer tarandus 
platyrhynchus) and its food base: plant-herbivore 
interactions in a high-arctic ecosystem 
  2008 Jiska van Dijk ph.d 
Biology 
Wolverine foraging strategies in a multiple-use 
landscape 
  2008 Flora John Magige ph.d 
Biology 
The ecology and behaviour of the Masai Ostrich 
(Struthio camelus massaicus) in the Serengeti 
Ecosystem, Tanzania 
  2008 Bernt Rønning ph.d 
Biology 
Sources of inter- and intra-individual 
variation in basal metabolic rate in the zebra 
finch, (Taeniopygia guttata) 
  2008 Sølvi Wehn ph.d  
Biology 
Biodiversity dynamics in semi-natural 
mountain landscapes.  
- A study of consequences of changed 
agricultural practices in Eastern 
Jotunheimen 
  2008 Trond Moxness 
Kortner 
ph.d 
Biology 
"The Role of Androgens on previtellogenic 
oocyte growth in Atlantic cod (Gadus 
morhua): Identification and patterns of 
differentially expressed genes in relation to 
Stereological Evaluations" 
  2008 Katarina Mariann 
Jørgensen 
Dr.Scient 
Biology 
The role of platelet activating factor in 
activation of growth arrested keratinocytes 
and re-epithelialisation 
  2008 Tommy Jørstad ph.d 
Biology 
Statistical Modelling of Gene Expression 
Data 
  2008 Anna Kusnierczyk ph.d 
Bilogy 
Arabidopsis thaliana Responses to Aphid 
Infestation 
  2008 Jussi Evertsen ph.d 
Biology 
Herbivore sacoglossans with photosynthetic 
chloroplasts 
 
  2008 John Eilif 
Hermansen 
ph.d 
Biology 
Mediating ecological interests between locals and 
globals by means of indicators. A study attributed to 
the asymmetry between stakeholders of tropical 
forest at Mt. Kilimanjaro, Tanzania 
  2008 Ragnhild Lyngved ph.d 
Biology 
Somatic embryogenesis in Cyclamen persicum. 
Biological investigations and educational aspects of 
cloning 
  2008 Line Elisabeth  
Sundt-Hansen 
ph.d 
Biology 
Cost of rapid growth in salmonid fishes 
 
  2008 Line Johansen ph.d 
Biology 
Exploring factors underlying fluctuations in white 
clover populations – clonal growth, population 
structure and spatial distribution 
  2009 Astrid Jullumstrø 
Feuerherm 
ph.d 
Biology 
Elucidation of molecular mechanisms for pro-
inflammatory phospholipase A2 in chronic disease 
  2009 Pål Kvello ph.d 
Biology 
Neurons forming the network involved in gustatory 
coding and learning in the moth Heliothis virescens: 
Physiological and morphological characterisation, 
and integration into a standard brain atlas 
  2009 Trygve Devold 
Kjellsen 
ph.d 
Biology 
Extreme Frost Tolerance in Boreal Conifers 
  2009 Johan Reinert Vikan ph.d 
Biology 
Coevolutionary interactions between common 
cuckoos Cuculus canorus and Fringilla finches 
  2009 Zsolt Volent ph.d 
Biology 
Remote sensing of marine environment: Applied 
surveillance with focus on optical properties of 
phytoplankton, coloured organic matter and 
suspended matter 
  2009 Lester Rocha ph.d 
Biology 
Functional responses of perennial grasses to 
simulated grazing and resource availability 
  2009 Dennis Ikanda ph.d 
Biology 
Dimensions of a Human-lion conflict: Ecology of 
human predation and persecution of African lions 
(Panthera leo) in Tanzania 
  2010 Huy Quang Nguyen ph.d 
Biology 
Egg characteristics and development of larval 
digestive function of cobia (Rachycentron canadum) 
in response to dietary treatments 
-Focus on formulated diets 
  2010 Eli Kvingedal ph.d 
Biology 
Intraspecific competition in stream salmonids: the 
impact of environment and phenotype 
  2010 Sverre Lundemo ph.d 
Biology 
Molecular studies of genetic structuring and 
demography in Arabidopsis from Northern Europe 
  2010 Iddi Mihijai Mfunda  ph.d 
Biology 
Wildlife Conservation and People’s livelihoods: 
Lessons Learnt and Considerations for 
Improvements. Tha Case of Serengeti Ecosystem, 
Tanzania 
  2010 Anton Tinchov 
Antonov 
ph.d 
Biology 
Why do cuckoos lay strong-shelled eggs? Tests of the 
puncture resistance hypothesis 
  2010 Anders Lyngstad ph.d Population Ecology of Eriophorum latifolium, a 
Biology Clonal Species in Rich Fen Vegetation 
  2010 Hilde Færevik ph.d 
Biology 
Impact of protective clothing on thermal and 
cognitive responses 
  2010 Ingerid Brænne Arbo ph.d 
Medical 
technolo
gy 
Nutritional lifestyle changes – effects of dietary 
carbohydrate restriction in healthy obese and 
overweight humans 
  2010 Yngvild Vindenes ph.d 
Biology 
Stochastic modeling of finite populations with 
individual heterogeneity in vital parameters 
  2010 Hans-Richard 
Brattbakk 
ph.d 
Medical 
technolo
gy 
The effect of macronutrient composition, insulin 
stimulation, and genetic variation on leukocyte gene 
expression and possible health benefits 
  2011 Geir Hysing Bolstad ph.d 
Biology 
Evolution of Signals: Genetic Architecture, Natural 
Selection and Adaptive Accuracy 
  2011 Karen de Jong ph.d 
Biology 
Operational sex ratio and reproductive behaviour in 
the two-spotted goby (Gobiusculus flavescens) 
  2011 Ann-Iren Kittang ph.d 
Biology 
Arabidopsis thaliana L. adaptation mechanisms to 
microgravity through the EMCS MULTIGEN-2 
experiment on the ISS:– The science of space 
experiment integration and adaptation to simulated 
microgravity 
  2011 
 
Aline Magdalena Lee ph.d 
Biology 
Stochastic modeling of mating systems and their 
effect on population dynamics and genetics 
  2011 
 
Christopher 
Gravningen Sørmo 
ph.d 
Biology 
Rho GTPases in Plants: Structural analysis of ROP 
GTPases; genetic and functional 
studies of MIRO GTPases in Arabidopsis thaliana 
  2011 Grethe Robertsen ph.d 
Biology 
Relative performance of  salmonid phenotypes across 
environments and competitive intensities 
  2011 
 
 
Line-Kristin Larsen ph.d 
Biology 
Life-history trait dynamics in experimental 
populations of guppy (Poecilia reticulata): the role of 
breeding regime and captive environment 
  2011 Maxim A. K. 
Teichert 
ph.d 
Biology 
Regulation in Atlantic salmon (Salmo salar): The 
interaction between habitat and density 
  2011 Torunn Beate 
Hancke 
ph.d 
Biology 
Use of Pulse Amplitude Modulated (PAM) 
Fluorescence and Bio-optics for Assessing 
Microalgal Photosynthesis and Physiology 
  2011 Sajeda Begum ph.d  
Biology 
Brood Parasitism in Asian Cuckoos: Different 
Aspects of Interactions between Cuckoos and their 
Hosts in Bangladesh 
  2011 Kari J. K. Attramadal ph.d 
Biology 
Water treatment as an approach to increase microbial 
control in the culture of cold water marine larvae 
  2011 Camilla Kalvatn 
Egset 
ph.d 
Biology 
The Evolvability of Static Allometry: A Case Study 
  2011 AHM Raihan Sarker ph.d 
Biology 
Conflict over the conservation of the Asian elephant 
(Elephas maximus) in Bangladesh 
  2011 Gro Dehli Villanger ph.d 
Biology 
Effects of complex organohalogen contaminant 
mixtures on thyroid hormone homeostasis in selected 
arctic marine mammals 
  2011 Kari Bjørneraas ph.d 
Biology 
Spatiotemporal variation in resource utilisation by a 
large herbivore, the moose 
  2011 John Odden ph.d 
Biology 
The ecology of a conflict: Eurasian lynx depredation 
on domestic sheep 
  2011 Simen Pedersen ph.d 
Biology 
Effects of native and introduced cervids on small 
mammals and birds 
  2011  Mohsen Falahati- ph.d Evolutionary consequences of seed banks and seed 
Anbaran Biology dispersal in Arabidopsis 
  2012 Jakob Hønborg 
Hansen 
ph.d 
Biology 
Shift work in the offshore vessel fleet: circadian 
rhythms and cognitive performance 
  2012 
 
2012 
Elin Noreen 
 
 Irja Ida Ratikainen 
ph.d 
Biology 
ph.d 
Biology 
Consequences of diet quality and age on life-history 
traits in a small passerine bird 
Theoretical and empirical approaches to studying 
foraging decisions: the past and future of behavioural 
ecology 
  2012 Aleksander Handå ph.d 
Biology 
Cultivation of mussels (Mytilus edulis):Feed 
requirements, storage and integration with salmon 
(Salmo salar) farming 
  2012 Morten Kraabøl ph.d 
Biology 
Reproductive and migratory challenges inflicted on 
migrant brown trour (Salmo trutta L) in a heavily 
modified river 
  2012 
 
2012 
Jisca Huisman 
 
Maria Bergvik 
ph.d 
Biology 
ph.d 
Biology 
Gene flow and natural selection in Atlantic salmon 
 
Lipid and astaxanthin contents and biochemical post-
harvest stability in Calanus finmarchicus 
    2012   Bjarte Bye Løfaldli ph.d 
Biology 
Functional and morphological characterization of 
central olfactory neurons in the model insect 
Heliothis virescens. 
  2012 Karen Marie 
Hammer 
ph.d 
Biology. 
Acid-base regulation and metabolite responses in 
shallow- and deep-living marine invertebrates during 
environmental hypercapnia 
  2012 Øystein Nordrum 
Wiggen 
ph.d 
Biology 
Optimal performance in the cold 
  2012 Robert Dominikus 
Fyumagwa 
Dr. 
Philos. 
Anthropogenic and natural influence on disease 
prevalence at the human –livestock-wildlife interface 
in the Serengeti ecosystem, Tanzania 
  2012 Jenny Bytingsvik ph.d 
Biology 
Organohalogenated contaminants (OHCs) in polar 
bear mother-cub pairs from Svalbard, Norway  
Maternal transfer, exposure assessment and thyroid 
hormone disruptive effects in polar bear cubs 
  2012 Christer Moe 
Rolandsen 
ph.d 
Biology 
The ecological significance of space use and 
movement patterns of moose in a variable 
environment 
  2012 Erlend Kjeldsberg 
Hovland 
ph.d 
Biology 
Bio-optics and Ecology in Emiliania huxleyi Blooms: 
Field and Remote Sensing Studies in Norwegian 
Waters 
  2012 Lise Cats Myhre ph.d 
Biology 
Effects of the social and physical environment on 
mating behaviour in a marine fish 
  2012 
 
2012 
Tonje Aronsen 
 
Bin Liu 
ph.d 
Biology 
ph.d 
Biology 
Demographic, environmental and evolutionary 
aspects of sexual selection 
Molecular genetic investigation of cell separation and 
cell death regulation in Arabidopsis thaliana 
  2013 Jørgen Rosvold ph.d 
Biology 
Ungulates in a dynamic and increasingly human 
dominated landscape – A millennia-scale perspective 
  2013 Pankaj Barah ph.d 
Biology 
Integrated Systems Approaches to Study  
Plant Stress Responses 
  2013 Marit Linnerud ph.d 
Biology 
Patterns in spatial and temporal variation in 
population abundances of vertebrates 
  2013 Xinxin Wang ph.d 
Biology 
Integrated multi-trophic aquaculture driven by
nutrient wastes released from Atlantic salmon 
(Salmo salar) farming
           2013 
 
Ingrid Ertshus 
Mathisen 
ph.d 
Biology 
Structure, dynamics, and regeneration capacity at the 
sub-arctic forest-tundra ecotone of northern Norway 
  and Kola Peninsula, NW Russia 
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Spatial distributions and productivity in salmonid 
populations 
Statistical methods for estimating intra- and inter-
population variation in genetic diversity 
Light in the dark – the role of irradiance in the high 
Arctic marine ecosystem during polar night  
The dynamics of sexual selection: effects of OSR, 
density and resource competition in a fish
Identification of marine organisms using 
chemotaxonomy and hyperspectral imaging 
Human-Wildlife Interaction in the Western Serengeti: 
Crop Raiding, Livestock Depredation and Bushmeat 
Utilisation 
Biofouling in the Norwegian Salmon Farming 
Industry
Phototaxis in Calanusfinmarchicus - light sensitivity 
and the influence of energy reserves and oil exposure 
Molecular and functional characterisation of 
signalling peptides of the IDA family in Arabidopsis 
thaliana 
Light responses in the marine diatom Phaeodactylum 
tricornutum 
Resource Allocation under Stress - Mechanisms and 
Strategies in a Long-Lived Bird 
Factors influencing African wild dog (Lycaon pictus)
habitat selection and ranging behaviour: conservation 
and management implications 
Application of Semantic Web Technology to 
establish knowledge management  and discovery in 
the Life Sciences 
Photoacclimation mechanisms and light responses in 
marine micro- and macroalgae 
Effects of rapidly fluctuating water levels on juvenile 
Atlantic salmon (Salmo salar L.)
 
 
 
    
  
